(Mark
One)
|
||
ý
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
For
the fiscal year ended December 31, 2008
|
||
OR
|
||
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
For
the transition period
from to
|
||
Commission
file number 0-32501
|
DELAWARE
|
33-0827593
|
|
(State
or Other Jurisdiction
of
Incorporation or Organization)
|
(I.R.S.
Employer
Identification
No.)
|
|
3020
CALLAN ROAD, SAN DIEGO, CALIFORNIA
|
92121
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Large
Accelerated Filer
o
|
Accelerated
Filer
ý
|
Non-Accelerated
Filer
o
|
Smaller
reporting company
o
|
(Do
not check if a smaller reporting company)
|
PART
I
|
|
PART
II
|
|
PART
III
|
|
PART
IV
|
|
Celution
®
Series
|
Region
|
Clinical
Applications
|
Regulatory
Status
|
Comments
|
900/MB
|
Japan
|
Cell
Banking
|
Approved
|
|
900/MB
|
Greece
|
Cell
Banking
|
CE
Mark
|
|
800/CRS
|
Europe
|
Cell
Processing for re-implantation or re-infusion into same patient
(General Processing)
|
CE
Mark
|
Post-marketing
studies underway for reconstructive surgery
|
Europe
|
Seeking
cosmetic & reconstructive claims
|
In
process
|
||
800/CV
|
Europe
|
Will
seek cardiovascular disease claims
|
In
clinical study
|
|
800/GP
|
Europe
|
Will
seek multiple specific surgical claims
|
Pre-clinical
|
Celution
®
Series
|
Region
|
Clinical
Applications
|
Regulatory
Status
|
Comments
|
700/CRS
|
USA
|
Will
seek reconstructive surgery claims
|
Pre-clinical
|
|
700/CV
|
USA
|
Will
seek cardiovascular disease claims
|
Pre-clinical
|
|
700/GP
|
USA
|
Will
seek multiple general surgical claims
|
Pre-clinical
|
|
600
|
Europe
|
Cell
Concentration
|
CE
Mark
|
Two
cardiac clinical trials underway: chronic and acute
|
200
|
USA
|
Blood
Processing
|
510
(k) clearance
|
·
|
Optimization
of the design, functionality and manufacturing process for the
Celution
®
System
family of products, single-use consumables and related instrumentation for
the entry of the device into the European reconstructive surgery market
and the StemSource
®
Cell Banking market in Europe and
Asia-Pacific;
|
·
|
Development
of the infrastructure and logistics in partnership with Green Hospital
Supply including building out a proprietary database and software
application and optimizing proprietary protocols, resulting in the first
sale in Japan of the StemSource
®
cell banking line to the University of
Kyoto;
|
·
|
Preparation
and initiation of a 70 patient European breast reconstruction
post-marketing clinical study using the Celution
®
System. The study is taking place across several centers and will measure
safety, volume retention as well as other metrics related to autologous
fat transfers enriched with the Celution
®
System output to correct partial mastectomy
defects;
|
·
|
Implementation
and continuing enrollment in two randomized, double blind, placebo
controlled, cardiovascular disease clinical trials in Europe for chronic
myocardial ischemia and heart
attacks.
|
·
|
Preparation
and submission of multiple regulatory filings in the United States,
Europe, and Japan related to various cell processing systems under
development;
|
·
|
Conducting
extensive pre-clinical safety and efficacy studies investigating the use
of adipose-derived stem and regenerative cells for reconstructive surgery,
spinal disc repair, renal failure, pancreatitis, stroke, and other
therapeutic applications;
|
·
|
Investigating
the cellular and molecular properties, composition, and characteristics of
stem and regenerative cells residing in adipose tissue towards improving
our intellectual property position and towards understanding how to
improve and control the therapeutic
products.
|
Regenerative
Cell Technology
|
Corporate
|
Total
|
||||
Manufacturing
|
20
|
—
|
20
|
|||
Research
& Development
|
57
|
—
|
57
|
|||
Sales
and Marketing
|
17
|
—
|
17
|
|||
General
& Administrative
|
—
|
32
|
32
|
|||
Total
|
94
|
32
|
126
|
High
|
Low
|
||||||
2007
|
|||||||
Quarter
ended March 31, 2007
|
$
|
7.00
|
$
|
4.56
|
|||
Quarter
ended June 30, 2007
|
$
|
6.69
|
$
|
5.36
|
|||
Quarter
ended September 30, 2007
|
$
|
6.67
|
$
|
4.85
|
|||
Quarter
ended December 31, 2007
|
$
|
6.50
|
$
|
4.88
|
|||
2008
|
|||||||
Quarter
ended March 31, 2008
|
$
|
6.44
|
$
|
4.62
|
|||
Quarter
ended June 30, 2008
|
$
|
8.56
|
$
|
4.75
|
|||
Quarter
ended September 30, 2008
|
$
|
7.97
|
$
|
5.00
|
|||
Quarter
ended December 31, 2008
|
$
|
5.65
|
$
|
1.76
|
|||
Plan Category
|
Number of securities to be issued
upon exercise of outstanding
options, warrants and rights
|
Weighted-average exercise price
of outstanding options, warrants
and rights
|
Number
of securities remaining
available
for future issuance under equity compensation
plans (excluding securities reflected
in column(a))
|
|||||
(a)
|
(b)
|
(c)
|
||||||
Equity
compensation plans approved by security holders (1)
|
3,810,395
|
$
|
4.65
|
—
|
||||
Equity
compensation plans not approved by security holders (2)
|
2,118,312
|
$
|
5.68
|
2,190,450
|
||||
Total
|
5,928,707
|
$
|
5.02
|
2,190,450
|
(1)
|
The
1997 Stock Option and Stock Purchase Plan expired on October 22,
2007.
|
(2)
|
The
maximum number of shares shall be cumulatively increased on the first
January 1 after the Effective Date, August 24, 2004, and each January 1
thereafter for 9 more years, by a number of shares equal to the lesser of
(a) 2% of the number of shares issued and outstanding on the immediately
preceding December 31, and (b) a number of shares set by the
Board.
|
2008
|
2007
|
2006
|
2005
|
2004
|
||||||||||||||||
Statements
of Operations Data:
|
||||||||||||||||||||
Product
revenues:
|
||||||||||||||||||||
Sales
to related party
|
$ | 28 | $ | 792 | $ | 1,451 | $ | 5,634 | $ | 4,085 | ||||||||||
Sales
to third parties
|
4,500 | — | — | — | 2,237 | |||||||||||||||
4,528 | 792 | 1,451 | 5,634 | 6,322 | ||||||||||||||||
Cost
of product revenues
|
1,854 | 422 | 1,634 | 3,154 | 3,384 | |||||||||||||||
Gross
profit (loss)
|
2,674 | 370 | (183 | ) | 2,480 | 2,938 | ||||||||||||||
Development
revenues:
|
||||||||||||||||||||
Development,
related party
|
774 | 5,168 | 6,057 | 51 | 158 | |||||||||||||||
Other,
related party
|
1,500 | — | — | — | — | |||||||||||||||
Research
grants and other
|
51 | 89 | 419 | 320 | 338 | |||||||||||||||
2,325 | 5,257 | 6,476 | 371 | 496 | ||||||||||||||||
Operating
expenses:
|
||||||||||||||||||||
Research
and development
|
17,371 | 20,020 | 21,977 | 15,450 | 10,384 | |||||||||||||||
Sales
and marketing
|
4,602 | 2,673 | 2,055 | 1,547 | 2,413 | |||||||||||||||
General
and administrative
|
11,727 | 14,184 | 12,547 | 10,208 | 6,551 | |||||||||||||||
Change
in fair value of option liabilities
|
1,060 | 100 | (4,431 | ) | 3,645 | — | ||||||||||||||
Restructuring
charge
|
— | — | — | — | 107 | |||||||||||||||
Equipment
impairment charge
|
— | — | — | — | 42 | |||||||||||||||
Total
operating expenses
|
34,760 | 36,977 | 32,148 | 30,850 | 19,497 | |||||||||||||||
Total
operating loss
|
(29,761 | ) | (31,350 | ) | (25,855 | ) | (27,999 | ) | (16,063 | ) | ||||||||||
Other
income (expense):
|
||||||||||||||||||||
Gain
on sale of assets
|
— | 1,858 | — | 5,526 | — | |||||||||||||||
Gain
on the sale of assets, related party
|
— | — | — | — | 13,883 | |||||||||||||||
Interest
income
|
230 | 1,028 | 708 | 299 | 252 | |||||||||||||||
Interest
expense
|
(420 | ) | (155 | ) | (199 | ) | (137 | ) | (177 | ) | ||||||||||
Other
income (expense)
|
(40 | ) | (46 | ) | (27 | ) | (55 | ) | 15 | |||||||||||
Equity
loss in investments
|
(45 | ) | (7 | ) | (74 | ) | (4,172 | ) | — | |||||||||||
Net
loss
|
$ | (30,036 | ) | $ | (28,672 | ) | $ | (25,447 | ) | $ | (26,538 | ) | $ | (2,090 | ) | |||||
Basic
and diluted net loss per share
|
$ | (1.12 | ) | $ | (1.25 | ) | $ | (1.53 | ) | $ | (1.80 | ) | $ | (0.15 | ) | |||||
Basic
and diluted weighted average common shares
|
26,882,431 | 22,889,250 | 16,603,550 | 14,704,281 | 13,932,390 | |||||||||||||||
Statements
of Cash Flows Data:
|
||||||||||||||||||||
Net
cash used in operating activities
|
$ | (33,389 | ) | $ | (29,995 | ) | $ | (16,483 | ) | $ | (1,101 | ) | $ | (12,574 | ) | |||||
Net
cash provided by investing activities
|
(393 | ) | 5,982 | 591 | 911 | 13,425 | ||||||||||||||
Net
cash provided by (used in) financing activities
|
34,928 | 26,576 | 16,787 | 5,357 | (831 | ) | ||||||||||||||
Net
increase (decrease) in cash
|
1,146 | 2,563 | 895 | 5,167 | 20 | |||||||||||||||
Cash
and cash equivalents at beginning of year
|
11,465 | 8,902 | 8,007 | 2,840 | 2,820 | |||||||||||||||
Cash
and cash equivalents at end of year
|
$ | 12,611 | $ | 11,465 | $ | 8,902 | $ | 8,007 | $ | 2,840 | ||||||||||
Balance
Sheet Data:
|
||||||||||||||||||||
Cash,
cash equivalents and short-term investments
|
$ | 12,611 | $ | 11,465 | $ | 12,878 | $ | 15,845 | $ | 13,419 | ||||||||||
Working
capital
|
10,090 | 4,168 | 7,392 | 10,459 | 12,458 | |||||||||||||||
Total
assets
|
25,609 | 21,507 | 24,868 | 28,166 | 25,470 | |||||||||||||||
Deferred
revenues, related party
|
16,474 | 18,748 | 23,906 | 17,311 | — | |||||||||||||||
Deferred
revenues
|
2,445 | 2,379 | 2,389 | 2,541 | 2,592 | |||||||||||||||
Option
liabilities
|
2,060 | 1,000 | 900 | 5,331 | — | |||||||||||||||
Deferred
gain on sale of assets
|
— | — | — | — | 5,650 | |||||||||||||||
Long-term
deferred rent
|
168 | 473 | 741 | 573 | 80 | |||||||||||||||
Long-term
obligations, less current portion
|
5,044 | 237 | 1,159 | 1,558 | 1,128 | |||||||||||||||
Total
stockholders’ equity (deficit)
|
$ | (7,717 | ) | $ | (9,400 | ) | $ | (10,813 | ) | $ | (6,229 | ) | $ | 12,833 |
·
|
Exceed
global Celution® System and StemSource sales target of $10 million in
2009
|
·
|
Expand
global distribution network in Europe and Asia-Pacific and related sales
impact
|
·
|
Expand
Celution® System product claims to include general and plastic surgery
procedures
|
·
|
Expand
Celution® System reimbursement in
Europe
|
·
|
Substantial
reduction in total operating
expenses
|
·
|
Complete
enrollment of RESTORE II in the second quarter of
2009
|
·
|
Report
preliminary RESTORE II results as early as the fourth quarter of 2009 on
patients who have been followed for six months at the time of
analysis
|
·
|
Introduce
complementary cosmetic and reconstructive surgery products in the U.S. in
the third quarter of 2009
|
·
|
Finalize
U.S. regulatory and clinical development and regulatory
strategy
|
·
|
Complete
enrollment in cardiovascular studies (PRECISE & APOLLO) and report
results in 2010
|
·
|
Olympus
paid $30,000,000 for its 50% interest in the Joint
Venture. Moreover, Olympus simultaneously entered into a
License/Joint Development Agreement with the Joint Venture and us to
develop a second generation commercial system and manufacturing
capabilities.
|
·
|
We
licensed our device technology, including the Celution
®
System platform and certain related intellectual property, to the Joint
Venture for use in future generation devices. These devices
will process and purify adult stem and regenerative cells residing in
adipose (fat) tissue for various therapeutic clinical
applications. In exchange for this license, we received a 50%
interest in the Joint Venture, as well as an initial $11,000,000 payment
from the Joint Venture; the source of this payment was the $30,000,000
contributed to the Joint Venture by Olympus. Moreover, upon
receipt of a CE mark for the first generation Celution
®
System platform in January 2006, we received an additional $11,000,000
development milestone payment from the Joint
Venture.
|
December
31, 2008
|
December
31, 2007
|
November
4, 2005
|
||||||||||
Expected
volatility of Cytori
|
68.00 | % | 60.00 | % | 63.20 | % | ||||||
Expected
volatility of the Joint Venture
|
68.00 | % | 60.00 | % | 69.10 | % | ||||||
Bankruptcy
recovery rate for Cytori
|
21.00 | % | 21.00 | % | 21.00 | % | ||||||
Bankruptcy
threshold for Cytori
|
$ | 16,740,000 | $ | 9,324,000 | $ | 10,780,000 | ||||||
Probability
of a change of control event for Cytori
|
2.80 | % | 2.17 | % | 3.04 | % | ||||||
Expected
correlation between fair values of Cytori and the Joint Venture in the
future
|
99.00 | % | 99.00 | % | 99.00 | % | ||||||
Risk
free interest rate
|
2.25 | % | 4.04 | % | 4.66 | % |
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Regenerative cell
technology
:
|
||||||||||||
Celution
®
Products
|
||||||||||||
Related
party
|
$ | 28,000 | $ | — | $ | — | ||||||
Third
party
|
4,500,000 | — | — | |||||||||
MacroPore
Biosurgery
:
|
||||||||||||
Spine
and orthopedic products
|
— | $ | 792,000 | $ | 1,451,000 | |||||||
Total
product revenues
|
$ | 4,528,000 | $ | 792,000 | $ | 1,451,000 | ||||||
%
attributable to Medtronic
|
— | 100 | % | 100 | % | |||||||
%
attributable to Olympus
|
0.6 | % | — | — |
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Regenerative cell
technology
:
|
||||||||||||
Cost
of product revenues
|
$ | 1,811,000 | $ | — | $ | — | ||||||
Share-based
compensation
|
43,000 | — | — | |||||||||
Total
regenerative cell technology
|
1,854,000 | — | — | |||||||||
MacroPore
Biosurgery
:
|
||||||||||||
Cost
of product revenues
|
— | 403,000 | 1,472,000 | |||||||||
Share-based
compensation
|
— | — | 88,000 | |||||||||
Share-based
compensation
|
— | 19,000 | 74,000 | |||||||||
Total
MacroPore Biosurgery
|
— | — | — | |||||||||
422,000 | 1,634,000 | |||||||||||
Total
cost of product revenues
|
$ | 1,854,000 | $ | 422,000 | $ | 1,634,000 | ||||||
Total
cost of product revenues as % of product revenues
|
40.9 | % | 53.3 | % | 112.6 | % | ||||||
·
|
The
increase in cost of product revenues for the year ended December 31, 2008
as compared to the same periods in 2007 and 2006 was due to Celution
®
System product sales which commenced in 2008. Cost of sales
included an economic benefit of approximately $347,000 related to material
cost and labor/overhead previously expensed as research and development
prior to commercialization date of March 1, 2008 that was sold during the
year ended December 31, 2008. Cost of product revenues as a
percentage of product revenues was 40.9% for the year ended December 31,
2008.
|
·
|
Cost
of product revenues included approximately $43,000 of share-based
compensation expense for the year ended December 31,
2008. There was no share-based compensation expense for the
years ended December 31, 2007 and 2006. For further details,
see share-based compensation discussion
below.
|
·
|
The
decrease in cost of product revenues for the year ended December 31, 2008
as compared to the same period in 2007 was due to our sale of
substantially all of the spine and orthopedic product line in May
2007. The decrease in cost of product revenues for the year
ended December 31, 2007 as compared to the same period in 2006 was due to
a decrease in production and sales in anticipation of the product line
sale in May 2007.
|
·
|
Cost
of product revenues includes approximately $0, $19,000 and $74,000 of
stock-based compensation expense for the years ended December 31, 2008,
2007 and 2006, respectively. For further details, see
stock-based compensation discussion
below.
|
·
|
During
the years ended December 31, 2008, 2007 and 2006, we recorded a provision
of $0, $0, and $88,000, respectively, related to excess and slow-moving
inventory. In 2006, this inventory was produced in anticipation of
stocking orders from Medtronic which did not
materialize.
|
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Regenerative cell
technology
:
|
||||||||||||
Milestone
revenue (Olympus)
|
$ | 774,000 | $ | 5,158,000 | $ | 5,905,000 | ||||||
Other
revenue (Olympus)
|
1,500,000 | — | — | |||||||||
Research
grant (NIH)
|
— | — | 310,000 | |||||||||
Regenerative
cell storage services
|
4,000 | 4,000 | 7,000 | |||||||||
Other
|
47,000 | 85,000 | 102,000 | |||||||||
Total
regenerative cell technology
|
2,325,000 | 5,247,000 | 6,324,000 | |||||||||
MacroPore
Biosurgery
:
|
||||||||||||
Development
(Senko)
|
— | 10,000 | 152,000 | |||||||||
Total
development revenues
|
$ | 2,325,000 | $ | 5,257,000 | $ | 6,476,000 |
·
|
We
recognize deferred revenues, related party, as development revenue when
certain performance obligations are met (i.e., using a proportional
performance approach). During the year ended December 31, 2008,
we recognized $774,000 of revenue associated with our arrangements with
Olympus. The revenue recognized in 2008 was a result of
completing two study milestones in the first
quarter.
|
·
|
The
research grant revenue related to our agreement with the National
Institutes of Health (“NIH”). Under this arrangement, the NIH
reimbursed us for “qualifying expenditures” related to research on
Adipose-Derived Cell Therapy for Myocardial Infarction. To
receive funds under the grant arrangement, we were required to (i)
demonstrate that we incurred “qualifying expenses,” as defined in the
grant agreement between the NIH and us, (ii) maintain a system of
controls, whereby we can accurately track and report all expenditures
related solely to research on Adipose-Derived Cell Therapy for Myocardial
Infarction, and (iii) file appropriate forms and follow appropriate
protocols established by the NIH.
|
·
|
Upon
notifying Senko of completion of the initial regulatory application to the
MHLW for the Thin Film product, we were entitled to a nonrefundable
payment of $1,250,000. We so notified Senko on
September 28, 2004, received payment in October of 2004, and recorded
deferred revenues of $1,250,000. As of December 31, 2006, of
the amount deferred, we have recognized development revenues of $371,000
($10,000 in 2007, $152,000 in 2006, $209,000 prior to
2006).
|
·
|
In
addition, we also received a $1,500,000 license fee that was recorded as a
component of deferred revenues in the accompanying balance
sheet. Because the $1,500,000 in license fees is potentially
refundable, such amounts will not be recognized as revenues until the
refund rights expire. Specifically, half of the license fee is
refundable if the parties agree commercialization is not achievable and a
proportional amount is refundable if we terminate the arrangement, other
than for material breach by Senko, before three years
post-commercialization.
|
·
|
We
are also entitled to a non-refundable payment of $250,000 once we achieve
commercialization.
|
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Regenerative cell
technology
:
|
||||||||||||
Regenerative
cell
technology
|
$ | 14,319,000 | $ | 12,889,000 | $ | 11,967,000 | ||||||
Development
milestone (Joint Venture)
|
2,546,000 | 6,293,000 | 7,286,000 | |||||||||
Research
grants
(NIH)
|
— | — | 479,000 | |||||||||
Stock-based
compensation
|
501,000 | 645,000 | 1,015,000 | |||||||||
Total
regenerative cell technology
|
17,366,000 | 19,827,000 | 20,747,000 | |||||||||
MacroPore
Biosurgery
:
|
||||||||||||
Bioresorbable
polymer implants
|
— | 111,000 | 1,027,000 | |||||||||
Development
milestone (Senko)
|
— | 80,000 | 178,000 | |||||||||
Thin
Film related
research
|
5,000 | — | — | |||||||||
Stock-based
compensation
|
— | 2,000 | 25,000 | |||||||||
Total
MacroPore
Biosurgery
|
5,000 | 193,000 | 1,230,000 | |||||||||
Total
research and development expenses
|
$ | 17,371,000 | $ | 20,020,000 | $ | 21,977,000 |
·
|
Regenerative
cell technology expenses relate to the development of a technology
platform that involves using adipose tissue as a source of autologous
regenerative cells for therapeutic applications. These
expenses, in conjunction with our continued development efforts related to
our Celution
®
System, result primarily from the broad expansion of our research and
development efforts enabled by the funding we received from Olympus in
2005 and 2006 and from other investors during the last few
years. Labor-related expenses, not including share-based
compensation, decreased by $1,494,000 for the year ended December 31, 2008
as compared to the same period in 2007 primarily due to the decrease in
headcount for our research and development department as a result of
achievement of commercialization and transfer of employees from research
and development to the manufacturing department. Professional
services expense increased by $310,000 from 2007 to 2008, primarily due to
increased use of consultants and temporary labor during the year ended
December 31, 2008. Pre-clinical and clinical study expense
decreased by $1,023,000 from 2007 to 2008 primarily due to a reduction in
pre-clinical study activity as we focus on our clinical studies.
Additionally, although the overall cost of a clinical trial is generally
higher than for a preclinical study, such costs are typically spread out
over a longer period of time. Expenses for supplies increased
by $352,000 from 2007 to 2008, primarily due to timing of use of inventory
supplies for research purposes and purchases of production supplies prior
to the related product line
commercialization.
|
·
|
Professional
services expense (including pre-clinical and clinical study costs)
decreased by $1,163,000 from 2006 to 2007, of which $422,000 was
attributed to a decrease in pre-clinical and clinical study expense
primarily due to a transition in focus from pre-clinical studies to
clinical studies. Rent and utilities expense decreased by
$316,000 from 2006 to 2007 primarily due the termination of leases at our
Top Gun location in San Diego, CA. These decreases were offset
by an increase in travel expense of $389,000 and an increase in repair and
maintenance expense of $382,000 from 2006 to
2007.
|
·
|
Expenditures
related to the Joint Venture with Olympus, which are included in the
variation analysis above, include costs that are necessary to support the
commercialization of future generation devices, including the next
generation Celution® device. These development activities,
which began in November 2005, include performing pre-clinical and clinical
studies, seeking regulatory approval, and performing product development
related to therapeutic applications for adipose stem and regenerative
cells for multiple large markets. For the years ended December
31, 2008, 2007 and 2006, costs associated with the development of the
device were $2,546,000, $6,293,000 and $7,286,000,
respectively. These expenses were comprised of $1,310,000,
$3,217,000 and $3,663,000 in labor and related benefits, $706,000,
$1,973,000 and $2,405,000 in consulting and other professional services,
$111,000, $567,000 and $872,000 in supplies and $419,000, $536,000 and
$346,000 in other miscellaneous expense,
respectively.
|
·
|
In
2004, we entered into an agreement with the NIH to reimburse us for up to
$950,000 (Phase I $100,000 and Phase II $850,000) in “qualifying
expenditures” related to research on Adipose-Derived Cell Therapy for
Myocardial Infarction. For the year ended December 31, 2006, we incurred
$479,000 of direct expenses relating entirely to Phase I and
II. Of these expenses, $169,000 were not reimbursed in
2006. To date, we have incurred $1,125,000 of direct expenses
($180,000 of which were not reimbursed) relating to both Phases I and II
of the agreement. There were no comparable expenditures in 2008
and 2007 as our work under this NIH agreement was completed during
2006.
|
·
|
Stock-based
compensation for the regenerative cell technology segment of research and
development was $501,000, $645,000 and $1,015,000 for the years ended
December 31, 2008, 2007 and 2006, respectively. See stock-based
compensation discussion below for more
details.
|
·
|
Our
bioresorbable surgical implants platform technology is used for
development of spine and orthopedic products and Thin Film
products. Research and development expenses for bioresorbable
polymer implants substantially decreased in 2007 and were essentially
ceased by 2008, due to the termination of spine and orthopedics product
research upon sale of substantially all of this product line in May
2007.
|
·
|
Under
a distribution agreement with Senko, we are responsible for the completion
of the initial regulatory application to the MHLW and commercialization of
the Thin Film product line in Japan. Commercialization occurs
when one or more Thin Film product registrations are completed with the
MHLW. During the years ended December 31, 2007 and 2006, we
incurred $80,000 and $178,000, respectively, of expenses related to this
regulatory and registration process. We did not incur any
expenses related to this regulatory and registration process for the year
ended December 31, 2008.
|
·
|
Share-based
compensation for the MacroPore Biosurgery segment of research and
development for the years ended December 31, 2007 and 2006 was $2,000 and
$25,000, respectively. There were no share-based compensation
expenses for the MacroPore Biosurgery segment of research and development
for the year ended December 31, 2008. See share-based
compensation discussion below for more
details.
|
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Regenerative cell
technology
:
|
||||||||||||
International
sales and marketing
|
$ | 4,065,000 | $ | 2,231,000 | $ | 1,271,000 | ||||||
Stock-based
compensation
|
361,000 | 265,000 | 517,000 | |||||||||
Total
regenerative cell technology
|
4,426,000 | 2,496,000 | 1,788,000 | |||||||||
MacroPore
Biosurgery
:
|
||||||||||||
General
corporate marketing
|
— | 21,000 | 154,000 | |||||||||
International
sales and marketing
|
176,000 | 156,000 | 104,000 | |||||||||
Stock-based
compensation
|
— | — | 9,000 | |||||||||
Total
MacroPore Biosurgery
|
176,000 | 177,000 | 267,000 | |||||||||
Total
sales and marketing
|
$ | 4,602,000 | $ | 2,673,000 | $ | 2,055,000 |
·
|
The
increase in international sales and marketing expense for the year ended
December 31, 2008 as compared to the same period in 2007 was mainly
attributed to the increase in salary and related benefits expense of
$974,000, not including share-based compensation, an increase in travel
related expenses of $321,000, and an increase in printing, supplies, and
postage of $155,000, which are due to our emphasis in seeking strategic
alliances and/or co-development partners for our regenerative cell
technology as well as sales and marketing efforts related to our
commercialization activities.
|
·
|
Stock-based
compensation for the regenerative cell segment of sales and marketing for
the year ended December 31, 2008, 2007 and 2006 was $361,000, $265,000 and
$517,000, respectively. See stock-based compensation discussion
below for more details.
|
·
|
General
corporate marketing expenditures relate to expenditures for maintaining
our corporate image and reputation within the research and surgical
communities relevant to bioresorbable
implants. Expenditures in this area declined to $0 in
2008 from $21,000 in 2007 and $154,000 in 2006 as we focused on our
regenerative cell technology business and shifted our focus from our spine
and orthopedic implant business.
|
·
|
International
sales and marketing expenditures relate to costs associated with
developing an international bioresorbable Thin Film distributor and
supporting a bioresorbable Thin Film sales office in
Japan.
|
·
|
Stock-based
compensation for the MacroPore Biosurgery segment of sales and marketing
for the years ended December 31, 2006 was $9,000. There was no
stock-based compensation for the MacroPore Biosurgery segment of sales and
marketing for the years ended December 31, 2008 and 2007. See
stock-based compensation discussion below for more
details.
|
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
General
and administrative
|
$ | 10,375,000 | $ | 12,805,000 | $ | 10,967,000 | ||||||
Stock-based
compensation
|
1,352,000 | 1,379,000 | 1,580,000 | |||||||||
Total
general and administrative expenses
|
$ | 11,727,000 | $ | 14,184,000 | $ | 12,547,000 |
·
|
General
and administrative expense, for the year ended December 31, 2008 as
compared to the same period in 2007 decreased by $2,457,000. An
overall decrease in general and administrative expenses (excluding
share-based compensation) occurred primarily from a decrease in legal fees
related to the ‘231 Patent (see below) of $1,793,000 and decrease
in salary and related benefit expense, excluding share-based
compensation) of $729,000 for the year ended December 31, 2008 as compared
to the same periods in 2007.
|
·
|
General
and administrative expense, for the year ended December 31, 2007 as
compared to the same period in 2006 increased by
$1,637,000. This was primarily a result of increases in salary
and related benefit expense of $802,000 and increases in professional
services of $1,160,000, offset by a decrease in stock-based compensation
of $201,000 for the year ended December 31, 2007 as compared with
2006. The increase in salary and related benefit expense was
mainly attributed to an increase in headcount. The increase in
professional services was mainly attributed to an increase of $266,000 in
consulting services, increases in accounting fees of $196,000, and an
increase in legal expenses of $863,000, partly incurred in connection with
the 231 Patent (see below), offset by a decrease in other professional
services of $165,000. In addition, we incurred a non-recurring
fee of $322,000 related to our February 2007 sale of common
stock.
|
·
|
We
have incurred substantial legal expenses in connection with the University
of Pittsburgh’s lawsuit. Although we are not litigants and are
not responsible for any settlement costs, if we are not successful in
overturning the Court’s decision on the ‘231 Patent, our license rights to
the ‘231 Patent will be lost. Since our current products and
products under development do not practice the ‘231 Patent, our primary
ongoing business activities and product development pipeline should not be
affected by the Court’s decision. Although the ‘231 Patent is unrelated to
our current products and product pipeline, we believe that the ‘231 Patent
and/or the other technology licensed from UC may have long term potential
to be useful for future product developments, and so we have elected to
support UC’s legal efforts in the appeal of the Court’s final
order. The amended license agreement we signed with UC in the
third quarter of 2006 clarified that we are responsible for patent
prosecution and litigation costs related to this lawsuit. In
the years ended December 31, 2008, 2007 and 2006, we expensed $625,000,
$2,418,000 and $2,189,000, respectively, for legal fees related to this
license. Our legal expenses related to this lawsuit and
the appeal will fluctuate depending upon the activity incurred during each
period.
|
·
|
Stock-based
compensation related to general and administrative expense for the years
ended December 31, 2007, 2006 and 2005 was $1,352,000, $1,379,000 and
$1,580,000, respectively. See stock-based compensation
discussion below for more details.
|
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Regenerative cell
technology
:
|
||||||||||||
Cost
of product revenues
|
$ | 43,000 | $ | — | $ | — | ||||||
Research
and development related
|
501,000 | 645,000 | 1,015,000 | |||||||||
Sales
and marketing related
|
361,000 | 265,000 | 517,000 | |||||||||
Total
regenerative cell technology
|
905,000 | 910,000 | 1,532,000 | |||||||||
MacroPore
Biosurgery
:
|
||||||||||||
Cost
of product revenues
|
— | 19,000 | 74,000 | |||||||||
Research
and development related
|
— | 2,000 | 25,000 | |||||||||
Sales
and marketing related
|
— | — | 9,000 | |||||||||
Total
MacroPore Biosurgery
|
— | 21,000 | 108,000 | |||||||||
General
and administrative related
|
1,352,000 | 1,379,000 | 1,580,000 | |||||||||
Total
stock-based compensation
|
$ | 2,257,000 | $ | 2,310,000 | $ | 3,220,000 |
·
|
Of
the $910,000 charge to stock-based compensation for the year ended
December 31, 2007, $6,000 related to award modifications for the
termination of the employment of our Vice President of Research,
Regenerative Cell Technology. The charge reflects the incremental fair
value of (a) the accelerated unvested stock options and (b) the extended
vested stock options (over the fair value of the original awards at the
modification date). There will be no further charges related
these modifications.
|
·
|
In
the first quarter of 2006, we issued 2,500 shares of restricted common
stock to a non-employee scientific advisor. The stock is
restricted in that it cannot be sold for a specified period of
time. There are no vesting requirements. Because the
shares issued are not subject to additional future vesting or service
requirements, the stock-based compensation expense of $18,000 recorded in
the first quarter of 2006 constitutes the entire expense related to this
grant, and no future period charges will be reported. The
scientific advisor also receives cash consideration as services are
performed.
|
·
|
During
the first quarter of 2008, we issued to our officers and directors stock
options to purchase up to 450,000 shares of our common stock, with a
four-year graded vesting schedule for our officers and two-year graded
vesting for our directors. The grant date fair value of option awards
granted to our officers and directors was $2.73 per share. The resulting
share-based compensation expense of $1,230,000, net of estimated
forfeitures, will be recognized as expense over the respective service
periods.
|
·
|
During
the first quarter of 2007, we issued to our officers and directors stock
options to purchase up to 410,000 shares of our common stock, with a
four-year vesting schedule for our officers and 24-month graded vesting
for our directors. The grant date fair value of option awards granted to
our officers and directors was $3.82 and $3.70 per share, respectively.
The resulting share-based compensation expense of $1,480,000, net of
estimated forfeitures, will be recognized as expense over the respective
vesting periods.
|
·
|
Of
the $1,379,000 charge to stock-based compensation for the year ended
December 31, 2007, $58,000 related to award modifications for the
termination of the employment of two employees. The charge
reflects the incremental fair value of (a) the accelerated unvested stock
options and (b) the extended vested stock options (over the fair value of
the original awards at the modification date). There will be no
further charges related these
modifications.
|
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Change
in fair value of option liability.
|
$ | — | $ | — | $ | (3,731,000 | ) | |||||
Change
in fair value of put option liability
|
1,060,000 | 100,000 | (700,000 | ) | ||||||||
Total
change in fair value of option liabilities.
|
$ | 1,060,000 | $ | 100,000 | $ | (4,431,000 | ) |
·
|
We
granted Olympus an option to acquire 2,200,000 shares of our common stock
in 2005. The exercise price of the option shares was $10 per
share. We had accounted for this grant as a liability because
had the option been exercised, we would have been required to deliver
listed shares of our common stock to settle the option
shares. In accordance with EITF 00-19, “Accounting for
Derivative Financial Instruments Indexed to, and Potentially Settled in, a
Company’s Own Stock,” the fair value of this option was re-measured at the
end of each quarter, using the Black-Scholes option pricing model, with
the movement in fair value reported in the statement of operations as a
change in fair value of option liabilities. This option expired
unexercised on December 31, 2006.
|
·
|
In
reference to the Joint Venture, the Shareholders’ Agreement between Cytori
and Olympus provides that in certain specified circumstances of insolvency
or if we experience a change in control, Olympus will have the rights to
(i) repurchase our interests in the Joint Venture at the fair value of
such interests or (ii) sell its own interests in the Joint Venture to us
at the higher of (a) $22,000,000 or (b) the Put’s fair
value. The value of the Put has been classified as a
liability.
|
December
31, 2008
|
December
31, 2007
|
December
31, 2006
|
||||||||||
Expected
volatility of Cytori
|
68.00 | % | 60.00 | % | 66.00 | % | ||||||
Expected
volatility of the Joint Venture
|
68.00 | % | 60.00 | % | 56.60 | % | ||||||
Bankruptcy
recovery rate for Cytori
|
21.00 | % | 21.00 | % | 21.00 | % | ||||||
Bankruptcy
threshold for Cytori
|
$ | 16,740,000 | $ | 9,324,000 | $ | 10,110,000 | ||||||
Probability
of a change of control event for Cytori
|
2.80 | % | 2.17 | % | 1.94 | % | ||||||
Expected
correlation between fair values of Cytori and the Joint Venture in the
future
|
99.00 | % | 99.00 | % | 99.00 | % | ||||||
Risk
free interest rate
|
2.25 | % | 4.04 | % | 4.71 | % |
Carrying
Value Prior to Disposition
|
||||
Inventory
|
$ | 94,000 | ||
Other
current assets
|
17,000 | |||
Assets
held for sale
|
436,000 | |||
Goodwill
|
465,000 | |||
$ | 1,012,000 |
For
the years ended December 31,
|
||||||||
2007
|
2006
|
|||||||
Revenues
|
$ | 792,000 | $ | 1,451,000 | ||||
Cost
of product revenues
|
(422,000 | ) | (1,634,000 | ) | ||||
Research
& development
|
(113,000 | ) | (1,052,000 | ) | ||||
Sales
& marketing
|
(21,000 | ) | (163,000 | ) |
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Interest
income
|
$ | 230,000 | $ | 1,028,000 | $ | 708,000 | ||||||
Interest
expense
|
(420,000 | ) | (155,000 | ) | (199,000 | ) | ||||||
Other
income (expense)
|
(40,000 | ) | (46,000 | ) | (27,000 | ) | ||||||
Total
|
$ | (230,000 | ) | $ | 827,000 | $ | 482,000 |
·
|
Interest
income decreased for the year December 31, 2008 as compared to the same
period in 2007 due to a decrease in interest rates and cash balance
available for investment. Interest income increased in 2007 as
compared to 2006 due to a larger balance of funds available for
investment, as a result of (i) the sale of common stock and common stock
warrants under the shelf registration statement in February 2007, (ii)
proceeds from the common stock private placement to Green Hospital Supply,
Inc. in April 2007, and (iii) proceeds from the sale of our bioresorbable
spine and orthopedic surgical implant product line to Kensey Nash in May
2007.
|
·
|
Interest
expense increased in 2008 as compared to 2007 due to interest incurred as
well as non-cash amortization of debt issuance costs and debt discount
associated with a new term loan. In October 2008, we entered
into a secured Loan Agreement with General Electric Capital Corporation
and Silicon Valley Bank (“Lenders”) to borrow up to
$15,000,000. An initial term loan of $7,500,000, less fees and
expenses, funded on October 14, 2008. Interest expense
decreased in 2007 as compared to 2006 due to the lower principal balances
on our long-term equipment-financed borrowings, which were fully repaid in
2008.
|
·
|
The
changes in other income (expense) in 2008, 2007 and 2006 resulted
primarily from changes in foreign currency exchange
rates.
|
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Equity
loss from investment in joint venture
|
$ | (45,000 | ) | $ | (7,000 | ) | $ | (74,000 | ) |
Years
ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Cash
and cash equivalents
|
$ | 12,611,000 | $ | 11,465,000 | $ | 8,902,000 | ||||||
Short-term
investments, available for sale
|
— | — | 3,976,000 | |||||||||
Total
cash and cash equivalents and short-term investments, available for
sale
|
$ | 12,611,000 | $ | 11,465,000 | $ | 12,878,000 | ||||||
Current
assets
|
$ | 17,225,000 | $ | 12,238,000 | $ | 13,978,000 | ||||||
Current
liabilities
|
7,135,000 | 8,070,000 | 6,586,000 | |||||||||
Working
capital
|
$ | 10,090,000 | $ | 4,168,000 | $ | 7,392,000 |
·
|
Issuing
stock in pre-IPO transactions, a 2000 initial public offering in Germany,
and stock option exercises,
|
·
|
Generating
revenues,
|
·
|
Selling
the bioresorbable implant CMF product line in September
2002,
|
·
|
Selling
the bioresorbable implant Thin Film product line (except for the territory
of Japan), in May 2004,
|
·
|
Licensing
distribution rights to Thin Film in Japan, in exchange for an upfront
license fee in July 2004 and an initial development milestone payment in
October 2004,
|
·
|
Obtaining
a modest amount of capital equipment long-term
financing,
|
·
|
Selling
1,100,000 shares of common stock to Olympus under an agreement which
closed in May 2005,
|
·
|
Receiving
upfront and milestone fees from our Joint Venture with Olympus, which was
entered into in November 2005,
|
·
|
Receiving
funds in exchange for granting Olympus an exclusive right to negotiate in
February 2006,
|
·
|
Receiving
$16,219,000 in net proceeds from a common stock sale under the shelf
registration statement in August
2006,
|
·
|
Receiving
$19,901,000 in net proceeds from the sale of common stock plus common
stock warrants under the shelf registration statement in February
2007,
|
·
|
Receiving
$6,000,000 in net proceeds from a private placement to Green Hospital
Supply, Inc. in April 2007, and
|
·
|
Receiving
gross proceeds of $3,175,000 from the sale of our bioresorbable spine and
orthopedic surgical implant product line to Kensey Nash in May
2007.
|
·
|
Receiving
$12,000,000 in net proceeds from a private placement to Green Hospital
Supply, Inc. during first half
2008.
|
·
|
Receiving
$17,000,000 in gross proceeds in August 2008 from a private placement of
2,825,517 unregistered shares of common stock and 1,412,758 common stock
warrants (with an original exercise price of $8.50 per share) to a
syndicate of investors including Olympus Corporation, who acquired
1,000,000 unregistered shares and 500,000 common stock warrants in
exchange for $6,000,000 of the total proceeds
raised.
|
·
|
Obtaining
a term loan of $7,500,000 from General Electric Capital Corporation and
Silicon Valley Bank (Lenders) in October
2008.
|
Payments
due by period
|
||||||||||||||||||||
Contractual
Obligations
|
Total
|
Less
than 1
year
|
1
– 3 years
|
3
– 5 years
|
More
than
5
years
|
|||||||||||||||
Long-term
obligations
|
$ | 7,914,000 | $ | 2,047,000 | $ | 5,847,000 | $ | 20,000 | $ | — | ||||||||||
Interest
commitment on long-term obligations
|
1,376,000 | 741,000 | 628,000 | 7,000 | — | |||||||||||||||
Operating
lease obligations
|
2,746,000 | 1,754,000 | 899,000 | 85,000 | 8,000 | |||||||||||||||
Minimum
purchase requirements
|
2,125,000 | 850,000 | 1,275,000 | — | — | |||||||||||||||
Pre-clinical
research study obligations
|
563,000 | 563,000 | — | — | — | |||||||||||||||
Clinical
research study obligations
|
5,839,000 | 4,000,000 | 1,839,000 | — | — | |||||||||||||||
Total
|
$ | 20,563,000 | $ | 9,955,000 | $ | 10,488,000 | $ | 112,000 | $ | 8,000 |
Years
Ended
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Net
cash used in operating activities
|
$ | (33,389,000 | ) | $ | (29,995,000 | ) | $ | (16,483,000 | ) | |||
Net
cash provided by (used in) investing activities
|
(393,000 | ) | 5,982,000 | 591,000 | ||||||||
Net
cash provided by financing activities
|
34,928,000 | 26,576,000 | 16,787,000 |
·
|
Fees
for achieving certain defined milestones under research and/or development
arrangements.
|
·
|
Product
sales, and
|
·
|
Payments
under license or distribution
agreements.
|
·
|
A
distribution license fee (which was paid at the outset of the
arrangement),
|
·
|
Milestone
payments for achieving commercialization of the Thin Film product line in
Japan,
|
·
|
Training
for representatives of Senko,
|
·
|
Sales
of Thin Film products to Senko, and
|
·
|
Royalty
payments on future product sales made by Senko to its end
customers.
|
·
|
The
delivered element has stand alone value to the
customer,
|
·
|
There
is objective evidence of the fair value of the remaining undelivered
elements, and
|
·
|
If
the arrangement contains a general right of return related to any products
delivered, delivery of the remaining goods and services is probable and
within the complete control of the
seller.
|
·
|
Granting
the Joint Venture (which Olympus is considered to control) an exclusive
and perpetual manufacturing license to our device technology, including
the Celution® System platform and certain related intellectual property;
and
|
·
|
Completing
certain pre-clinical and clinical studies, assisting with product
development and seeking regulatory approval and/or clearances toward
commercialization of the Celution® System
platform.
|
·
|
Product
Revenues
|
o
|
We
recognize revenue from product sales when the following fundamental
criteria are met: (i) persuasive evidence of an arrangement exists, (ii)
delivery has occurred, (iii) the price to the customer is fixed or
determinable and (iv) collection of the resulting accounts receivable is
reasonably assured.
|
·
|
Upfront
License Fees/Milestones
|
o
|
As
part of the Senko Distribution Agreement, we received an upfront license
fee upon execution of the arrangement, which, as noted previously, was not
separable under EITF 00-21. Accordingly, the license has been
combined with the development (milestones) element to form a single
accounting unit. This single element of $3,000,000 in fees
includes $1,500,000 which is potentially refundable. We have
recognized, and will continue to recognize, the non-contingent fees
allocated to this combined element as revenues as we complete each of the
performance obligations associated with the milestones component of this
combined deliverable. Note that the timing of when we have
recognized revenues to date does not
|
correspond
with the cash we received upon achieving certain
milestones. For example, the first such milestone payment for
$1,250,000 became payable to us when we filed a commercialization
application with the Japanese regulatory authorities. However,
we determined that the payment received was not commensurate with the
level of effort expended, particularly when compared with other steps we
believe are necessary to commercialize the Thin Film product line in
Japan. Accordingly, we did not recognize the entire $1,250,000
received as revenues, but instead all but $371,000 of this amount is
classified as deferred revenues. Approximately $371,000
($10,000 in 2007, $152,000 in 2006, $51,000 in 2005 and $158,000 in 2004)
has been recognized to date as development revenues based on our estimates
of the level of effort expended for completed milestones as compared with
the total level of effort we expect to incur under the arrangement to
successfully achieve regulatory approval of the Thin Film product line in
Japan. These estimates were subject to judgment and there may
be changes to these estimates as we continue to seek regulatory
approval. In fact there can be no assurance that
commercialization in Japan will ever be achieved, as we have yet to
receive approval from the MHLW for the Thin Film
product.
|
o
|
We
also received upfront fees as part of the Olympus arrangements (although,
unlike in the Senko agreement, these fees were
non-refundable). Specifically, in exchange for an upfront fee,
we granted the Joint Venture an exclusive, perpetual license to certain of
our intellectual property and agreed to perform additional development
activities. This upfront fee has been recorded in the liability
account entitled deferred revenues, related party, on our consolidated
balance sheet. Similar to the Senko agreement, we expect to
recognize revenues from the combined license/development accounting unit
as we perform our obligations under the agreements, as this represents our
final obligation underlying the combined accounting
unit. Specifically, we have recognized revenues from the
license/development accounting unit using a “proportional performance”
methodology, resulting in the de-recognition of amounts recorded in the
deferred revenues, related party, account as we complete various
milestones underlying the development services. Proportional
performance methodology was elected due to the nature of our development
obligations and efforts in support of the Joint Venture (“JV”), including
product development activities, and regulatory efforts to support the
commercialization of the JV products. The application of this methodology
uses the achievement of R&D milestones as outputs of value to the
JV. We received up-front, non-refundable payments in connection
with these development obligations, which we have broken down into
specific R&D milestones that are definable and substantive in nature,
and which will result in value to the JV when achieved. Revenue
will be recognized as the above mentioned R&D milestones are
completed. We established the R&D milestones based upon our
development obligations to the JV and the specific R&D support
activities to be performed to achieve these obligations. Our
R&D milestones consist of the following primary performance
categories: product development, regulatory approvals, and
generally associated pre-clinical and clinical
trials. Within each category are milestones that take
substantive effort to complete and are critical pieces of the overall
progress towards completion of the next generation product, which we are
obligated to support within the agreements entered into with
Olympus. To determine whether substantive effort was required
to achieve the milestones, we considered the external costs, required
personnel and relevant skill levels, the amount of time required to
complete each milestone, and the interdependent relationships between the
milestones, in that the benefits associated with the completion of one
milestone generally support and contribute to the achievement of the
next. Determination of the relative values assigned to each
milestone involved substantial judgment. The assignment process
was based on discussions with persons responsible for the development
process and the relative costs of completing each milestone. We
considered the costs of completing the milestones in allocating the
portion of the “deferred revenues, related party” account balance to each
milestone. Management believes that, while the costs incurred
in achieving the various milestones are subject to estimation, due to the
high correlation of such costs to outputs achieved, the use of external
contract research organization (“CRO”) costs and internal labor costs as
the basis for the allocation process provides management the ability to
accurately and reasonably estimate such costs. The accounting
policy described above could result in revenues being recorded in an
earlier accounting period than had other judgments or assumptions been
made by us.
|
·
|
Government
Grants
|
o
|
We
are at times eligible to receive grants from the NIH related to various
research activities. Revenues derived from reimbursement of
direct out-of-pocket expenses for research costs associated with grants
are recorded in compliance with EITF Issue No. 99-19, “Reporting
Revenue Gross as a Principal Versus Net as an Agent”, and EITF
Issue No. 01-14, “Income Statement Characterization of Reimbursements
Received for “Out-of-Pocket” Expenses Incurred”. In accordance with
the criteria established by these EITF Issues,
|
|
the
Company records grant revenue for the gross amount of the
reimbursement. The costs associated with these reimbursements are
reflected as a component of research and development expense in the
consolidated statements of operations. Additionally, research
arrangements we have with NIH, as well commercial enterprises such as
Olympus and Senko, are considered a key component of our central and
ongoing operations. Moreover, the government obtains rights
under the arrangement, in the same manner (but perhaps not to the same
extent) as a commercial customer that similarly contracts with us to
perform research activities. For instance, the government and
any authorized third parties may use our federally funded research and/or
inventions without payment of royalties to us. Accordingly, the
inflows from such arrangements are presented as revenues in the
consolidated statements of
operations.
|
·
|
Company
assets and liabilities, including goodwill, are allocated to each
reporting unit for purposes of completing the goodwill impairment
test.
|
·
|
The
carrying value of each reporting unit – that is, the sum of all of the net
assets allocated to the reporting unit – is then compared to its fair
value.
|
·
|
If
the fair value of the reporting unit is lower than its carrying amount,
goodwill may be impaired – additional testing is
required.
|
·
|
The
asset will be employed in or the liability relates to the operations of a
reporting unit.
|
·
|
The
asset or liability will be considered in determining the fair value of the
reporting unit.
|
·
|
Under
FIN 46R, an entity is a VIE if it has insufficient equity to finance its
activities. We recognized that the initial cash contributed to
the Joint Venture formed by Olympus and Cytori ($30,000,000) would be
completely utilized by the first quarter of 2006. Moreover, it
was highly unlikely that the Joint Venture would be able to obtain the
necessary financing from third party lenders without additional
subordinated financial support – such as personal guarantees by one or
both of the Joint Venture stockholders. Accordingly, the joint
venture will require additional financial support from Olympus and Cytori
to finance its ongoing operations, indicating that the Joint Venture is a
VIE. In fact, we contributed $300,000 and $150,000 in the
fourth quarter of 2007 and first quarter of 2006, respectively, to fund
the Joint Venture’s ongoing
operations.
|
·
|
Moreover,
Olympus has a contingent put option that would, in specified
circumstances, require Cytori to purchase Olympus’s interests in the Joint
Venture for a fixed amount of $22,000,000. Accordingly, Olympus
is protected in some circumstances from absorbing all expected losses in
the Joint Venture. Under FIN 46R, this means that Olympus may
not be an “at-risk” equity holder, although Olympus clearly has decision
rights over the operations of the Joint
Venture.
|
·
|
The
business operations of the Joint Venture will be most closely aligned to
those of Olympus (i.e., the manufacture of
devices).
|
·
|
Olympus
controls the Board of Directors, as well as the day-to-day operations of
the Joint Venture.
|
Item 8
. Financial Statements and Supplementary
Data
|
PART
I. FINANCIAL INFORMATION
|
||||||||||||||||
Item
1. Financial Statements
|
||||||||||||||||
/s/
KPMG LLP
|
/s/
KPMG LLP
|
As of December 31,
|
||||||||
2008
|
2007
|
|||||||
Assets
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 12,611,000 | $ | 11,465,000 | ||||
Accounts
receivable, net of allowance for doubtful accounts of $122,000 and $1,000
in 2008 and 2007, respectively
|
1,308,000 | 9,000 | ||||||
Inventories,
net
|
2,143,000 | — | ||||||
Other
current assets
|
1,163,000 | 764,000 | ||||||
Total
current assets
|
17,225,000 | 12,238,000 | ||||||
Property
and equipment, net
|
2,552,000 | 3,432,000 | ||||||
Investment
in joint venture
|
324,000 | 369,000 | ||||||
Other
assets
|
729,000 | 468,000 | ||||||
Intangibles,
net
|
857,000 | 1,078,000 | ||||||
Goodwill
|
3,922,000 | 3,922,000 | ||||||
Total
assets
|
$ | 25,609,000 | $ | 21,507,000 | ||||
Liabilities
and Stockholders’ Deficit
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable and accrued expenses
|
$ | 5,088,000 | $ | 7,349,000 | ||||
Current
portion of long-term obligations
|
2,047,000 | 721,000 | ||||||
Total
current liabilities
|
7,135,000 | 8,070,000 | ||||||
Deferred
revenues, related party
|
16,474,000 | 18,748,000 | ||||||
Deferred
revenues
|
2,445,000 | 2,379,000 | ||||||
Option
liability
|
2,060,000 | 1,000,000 | ||||||
Long-term
deferred rent
|
168,000 | 473,000 | ||||||
Long-term
obligations, less current portion
|
5,044,000 | 237,000 | ||||||
Total
liabilities
|
33,326,000 | 30,907,000 | ||||||
Commitments
and contingencies
|
||||||||
Stockholders’
deficit:
|
||||||||
Preferred
stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued
and outstanding in 2008 and 2007
|
— | — | ||||||
Common
stock, $0.001 par value; 95,000,000 shares authorized; 31,176,275 and
25,962,222 shares issued and 29,303,441 and 24,089,388 shares outstanding
in 2008 and 2007, respectively
|
31,000 | 26,000 | ||||||
Additional
paid-in capital
|
161,214,000 | 129,504,000 | ||||||
Accumulated
deficit
|
(162,168,000 | ) | (132,132,000 | ) | ||||
Treasury
stock, at cost
|
(6,794,000 | ) | (6,794,000 | ) | ||||
Amount
due from exercises of stock
options
|
— | (4,000 | ) | |||||
Total
stockholders’ deficit
|
(7,717,000 | ) | (9,400,000 | ) | ||||
Total
liabilities and stockholders’ deficit
|
$ | 25,609,000 | $ | 21,507,000 |
For the Years Ended December 31,
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Product
revenues:
|
||||||||||||
Related
party
|
$ | 28,000 | $ | 792,000 | $ | 1,451,000 | ||||||
Third
party
|
4,500,000 | — | — | |||||||||
4,528,000 | 792,000 | 1,451,000 | ||||||||||
Cost
of product revenues
|
1,854,000 | 422,000 | 1,634,000 | |||||||||
Gross
profit (loss)
|
2,674,000 | 370,000 | (183,000 | ) | ||||||||
Development
revenues:
|
||||||||||||
Development,
related party
|
774,000 | 5,158,000 | 5,905,000 | |||||||||
Other,
related party
|
1,500,000 | — | — | |||||||||
Development
|
— | 10,000 | 152,000 | |||||||||
Research
grants and other
|
51,000 | 89,000 | 419,000 | |||||||||
2,325,000 | 5,257,000 | 6,476,000 | ||||||||||
Operating
expenses:
|
||||||||||||
Research
and development
|
17,371,000 | 20,020,000 | 21,977,000 | |||||||||
Sales
and marketing
|
4,602,000 | 2,673,000 | 2,055,000 | |||||||||
General
and administrative
|
11,727,000 | 14,184,000 | 12,547,000 | |||||||||
Change
in fair value of option liabilities
|
1,060,000 | 100,000 | (4,431,000 | ) | ||||||||
Total
operating expenses
|
34,760,000 | 36,977,000 | 32,148,000 | |||||||||
Operating
loss
|
(29,761,000 | ) | (31,350,000 | ) | (25,855,000 | ) | ||||||
Other
income (expense):
|
||||||||||||
Gain
on sale of assets
|
— | 1,858,000 | — | |||||||||
Interest
income
|
230,000 | 1,028,000 | 708,000 | |||||||||
Interest
expense
|
(420,000 | ) | (155,000 | ) | (199,000 | ) | ||||||
Other
expense, net
|
(40,000 | ) | (46,000 | ) | (27,000 | ) | ||||||
Equity
loss from investment in joint venture
|
(45,000 | ) | (7,000 | ) | (74,000 | ) | ||||||
Total
other income (loss)
|
(275,000 | ) | 2,678,000 | 408,000 | ||||||||
Net
loss
|
(30,036,000 | ) | (28,672,000 | ) | (25,447,000 | ) | ||||||
Other
comprehensive income (loss) - unrealized holding income
(loss)
|
— | (1,000 | ) | 17,000 | ||||||||
Comprehensive
loss
|
$ | (30,036,000 | ) | $ | (28,673,000 | ) | $ | (25,430,000 | ) | |||
Basic
and diluted net loss per common share
|
$ | (1.12 | ) | $ | (1.25 | ) | $ | (1.53 | ) | |||
Basic
and diluted weighted average common shares
|
26,882,431 | 22,889,250 | 16,603,550 |
Accumulated
|
Amount
due
|
|||||||||||||||||||||||||||||||||||
Additional
|
Other
|
From
|
||||||||||||||||||||||||||||||||||
Common
Stock
|
Paid-in
|
Accumulated
|
Treasury
Stock
|
Comprehensive
|
Exercises
of
|
|||||||||||||||||||||||||||||||
Shares
|
Amount
|
Capital
|
Deficit
|
Shares
|
Amount
|
Income
(Loss)
|
Stock
Options
|
Total
|
||||||||||||||||||||||||||||
Balance
at December 31, 2005
|
18,194,283 | $ | 18,000 | $ | 82,196,000 | $ | (78,013,000 | ) | 2,872,834 | $ | (10,414,000 | ) | $ | (16,000 | ) | $ | — | $ | (6,229,000 | ) | ||||||||||||||||
Stock-based
compensation expense
|
— | — | 3,202,000 | — | — | — | — | — | 3,202,000 | |||||||||||||||||||||||||||
Issuance
of common stock under stock option plan
|
397,205 | 1,000 | 934,000 | — | — | — | — | — | 935,000 | |||||||||||||||||||||||||||
Compensatory
common stock awards
|
2,500 | — | 18,000 | — | — | — | — | — | 18,000 | |||||||||||||||||||||||||||
Sale
of common stock
|
2,918,255 | 3,000 | 16,216,000 | — | — | — | — | — | 16,219,000 | |||||||||||||||||||||||||||
Stock
issued for license amendment
|
100,000 | — | 487,000 | — | — | — | — | — | 487,000 | |||||||||||||||||||||||||||
Amount
due from exercises of stock options
|
— | — | — | — | — | — | — | (15,000 | ) | (15,000 | ) | |||||||||||||||||||||||||
Unrealized
gain on investments
|
— | — | — | — | — | — | 17,000 | — | 17,000 | |||||||||||||||||||||||||||
Net
loss for the year ended December 31, 2006
|
— | — | — | (25,447,000 | ) | — | — | — | — | (25,447,000 | ) | |||||||||||||||||||||||||
Balance
at December 31, 2006
|
21,612,243 | 22,000 | 103,053,000 | (103,460,000 | ) | 2,872,834 | (10,414,000 | ) | 1,000 | (15,000 | ) | (10,813,000 | ) | |||||||||||||||||||||||
Stock-based
compensation expense
|
— | — | 2,310,000 | — | — | — | — | — | 2,310,000 | |||||||||||||||||||||||||||
Issuance
of common stock under stock option plan
|
604,334 | 1,000 | 1,863,000 | — | — | — | — | — | 1,864,000 | |||||||||||||||||||||||||||
Sale
of common stock
|
3,745,645 | 3,000 | 19,898,000 | — | — | — | — | — | 19,901,000 | |||||||||||||||||||||||||||
Sale
of treasury stock
|
— | — | 2,380,000 | — | (1,000,000 | ) | 3,620,000 | — | — | 6,000,000 | ||||||||||||||||||||||||||
Amount
due from exercises of stock options
|
— | — | — | — | — | — | — | 11,000 | 11,000 | |||||||||||||||||||||||||||
Unrealized
loss on investments
|
— | — | — | — | — | — | (1,000 | ) | — | (1,000 | ) | |||||||||||||||||||||||||
Net
loss for the year ended December 31, 2007
|
— | — | — | (28,672,000 | ) | — | — | — | — | (28,672,000 | ) | |||||||||||||||||||||||||
Balance
at December 31, 2007
|
25,962,222 | 26,000 | 129,504,000 | (132,132,000 | ) | 1,872,834 | (6,794,000 | ) | — | (4,000 | ) | (9,400,000 | ) | |||||||||||||||||||||||
Stock-based
compensation expense
|
— | — | 2,257,000 | — | — | — | — | — | 2,257,000 | |||||||||||||||||||||||||||
Issuance
of common stock under stock option plan
|
388,536 | — | 790,000 | — | — | — | — | — | 790,000 | |||||||||||||||||||||||||||
Sale
of common stock
|
4,825,517 | 5,000 | 28,099,000 | — | — | — | — | — | 28,104,000 | |||||||||||||||||||||||||||
Amount
due from exercises of stock options
|
— | — | — | — | — | — | — | 4,000 | 4,000 | |||||||||||||||||||||||||||
Allocation
of fair value for debt warrants
|
— | — | 564,000 | — | — | — | — | — | 564,000 | |||||||||||||||||||||||||||
Net
loss for the year ended December 31, 2008
|
— | — | — | (30,036,000 | ) | — | — | — | — | (30,036,000 | ) | |||||||||||||||||||||||||
Balance
at December 31, 2008
|
31,176,275 | $ | 31,000 | $ | 161,214,000 | $ | (162,168,000 | ) | 1,872,834 | $ | (6,794,000 | ) | $ | — | $ | — | $ | (7,717,000 | ) |
For the Years Ended December 31,
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Cash
flows from operating activities:
|
||||||||||||
Net
loss
|
$ | (30,036,000 | ) | $ | (28,672,000 | ) | $ | (25,447,000 | ) | |||
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
||||||||||||
Depreciation
and amortization
|
1,533,000 | 1,616,000 | 2,120,000 | |||||||||
Amortization
of deferred financing costs and debt discount
|
178,000 | — | — | |||||||||
Inventory
provision
|
— | 70,000 | 88,000 | |||||||||
Warranty
provision (reversal)
|
(44,000 | ) | (65,000 | ) | (23,000 | ) | ||||||
Increase
(reduction) in allowance for doubtful accounts
|
121,000 | (1,000 | ) | (7,000 | ) | |||||||
Change
in fair value of option liabilities
|
1,060,000 | 100,000 | (4,431,000 | ) | ||||||||
Gain
on sale of assets
|
— | (1,858,000 | ) | — | ||||||||
Stock-based
compensation
|
2,257,000 | 2,310,000 | 3,220,000 | |||||||||
Stock
issued for license amendment
|
— | — | 487,000 | |||||||||
Equity
loss from investment in joint venture
|
45,000 | 7,000 | 74,000 | |||||||||
Increases
(decreases) in cash caused by changes in operating assets and
liabilities:
|
||||||||||||
Accounts
receivable
|
(1,420,000 | ) | 217,000 | 598,000 | ||||||||
Inventories
|
(2,143,000 | ) | — | 6,000 | ||||||||
Other
current assets
|
(147,000 | ) | (70,000 | ) | (90,000 | ) | ||||||
Other
assets
|
(63,000 | ) | (40,000 | ) | 30,000 | |||||||
Accounts
payable and accrued expenses
|
(2,217,000 | ) | 1,827,000 | 281,000 | ||||||||
Deferred
revenues, related party
|
(2,274,000 | ) | (5,158,000 | ) | 6,595,000 | |||||||
Deferred
revenues
|
66,000 | (10,000 | ) | (152,000 | ) | |||||||
Long-term
deferred rent
|
(305,000 | ) | (268,000 | ) | 168,000 | |||||||
Net
cash used in operating activities
|
(33,389,000 | ) | (29,995,000 | ) | (16,483,000 | ) | ||||||
Cash
flows from investing activities:
|
||||||||||||
Proceeds
from the sale and maturity of short-term investments
|
5,739,000 | 28,007,000 | 67,137,000 | |||||||||
Purchases
of short-term investments
|
(5,739,000 | ) | (24,032,000 | ) | (63,258,000 | ) | ||||||
Proceeds
from the sale of assets
|
— | 3,175,000 | — | |||||||||
Costs
from sale of assets
|
— | (305,000 | ) | — | ||||||||
Purchases
of property and equipment
|
(393,000 | ) | (563,000 | ) | (3,138,000 | ) | ||||||
Investment
in joint venture
|
— | (300,000 | ) | (150,000 | ) | |||||||
Net
cash provided by (used in) investing activities
|
(393,000 | ) | 5,982,000 | 591,000 | ||||||||
Cash
flows from financing activities:
|
||||||||||||
Principal
payments on long-term obligations
|
(958,000 | ) | (1,200,000 | ) | (952,000 | ) | ||||||
Proceeds
from long-term obligations
|
7,500,000 | — | 600,000 | |||||||||
Debt
issuance costs
|
(513,000 | ) | — | — | ||||||||
Proceeds
from exercise of employee stock options
|
795,000 | 1,875,000 | 920,000 | |||||||||
Proceeds
from sale of common stock
|
28,954,000 | 21,500,000 | 16,780,000 | |||||||||
Costs
from sale of common stock
|
(850,000 | ) | (1,599,000 | ) | (561,000 | ) | ||||||
Proceeds
from sale of treasury stock
|
— | 6,000,000 | — | |||||||||
Net
cash provided by financing activities
|
34,928,000 | 26,576,000 | 16,787,000 | |||||||||
Net
increase in cash and cash equivalents
|
1,146,000 | 2,563,000 | 895,000 | |||||||||
Cash
and cash equivalents at beginning of year
|
11,465,000 | 8,902,000 | 8,007,000 | |||||||||
Cash
and cash equivalents at end of year
|
$ | 12,611,000 | $ | 11,465,000 | $ | 8,902,000 |
For the Years Ended December 31,
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Supplemental
disclosure of cash flows information:
|
||||||||||||
Cash
paid during period for:
|
||||||||||||
Interest
|
$ | 180,000 | $ | 160,000 | $ | 201,000 | ||||||
Taxes
|
— | 2,000 | 1,000 | |||||||||
Supplemental
schedule of non-cash investing and financing activities:
|
||||||||||||
Fair
value of warrants allocated to additional paid in capital
|
$ | 564,000 | $ | — | $ | — | ||||||
Final
payment fee of the long-term debt
|
375,000 | |||||||||||
Amount
due from exercise of stock options
|
— | 4,000 | 15,000 |
1.
|
Organization
and Operations
|
2.
|
Summary
of Significant Accounting Policies
|
December 31, 2008
|
||||||||||||
Regenerative
Cell Technology
|
MacroPore
Biosurgery
|
Total
|
||||||||||
Other
intangibles, net:
|
||||||||||||
Beginning
balance
|
$ | 1,078,000 | $ | — | $ | 1,078,000 | ||||||
Amortization
|
(221,000 | ) | — | (221,000 | ) | |||||||
Ending
balance
|
857,000 | — | 857,000 | |||||||||
Goodwill,
net:
|
||||||||||||
Beginning
balance
|
3,922,000 | — | 3,922,000 | |||||||||
Disposal
of assets
|
— | — | — | |||||||||
Ending
balance
|
3,922,000 | — | 3,922,000 | |||||||||
Total
goodwill and other intangibles, net
|
$ | 4,779,000 | $ | — | $ | 4,779,000 | ||||||
Cumulative
amortization of other intangible assets
|
$ | 1,359,000 | $ | — | $ | 1,359,000 |
December 31, 2007
|
||||||||||||
Regenerative
Cell Technology
|
MacroPore
Biosurgery
|
Total
|
||||||||||
Other
intangibles, net:
|
||||||||||||
Beginning
balance
|
$ | 1,300,000 | $ | — | $ | 1,300,000 | ||||||
Amortization
|
(222,000 | ) | — | (222,000 | ) | |||||||
Ending
balance
|
1,078,000 | — | 1,078,000 | |||||||||
Goodwill,
net:
|
||||||||||||
Beginning
balance
|
3,922,000 | 465,000 | 4,387,000 | |||||||||
Disposal
of assets
|
— | (465,000 | ) | (465,000 | ) | |||||||
Ending
balance
|
3,922,000 | — | 3,922,000 | |||||||||
Total
goodwill and other intangibles, net
|
$ | 5,000,000 | $ | — | $ | 5,000,000 | ||||||
Cumulative
amortization of other intangible assets
|
$ | 1,138,000 | $ | — | $ | 1,138,000 |
2009
|
222,000
|
|||
2010
|
222,000
|
|||
2011
|
222,000
|
|||
2012
|
191,000
|
|||
$
|
857,000
|
·
|
In
2004, we received a nonrefundable payment of $1,250,000 from Senko after
filing an initial regulatory application with the Japanese Ministry of
Health, Labour and Welfare (“MHLW”) related to the Thin Film product
line. We initially recorded this payment as deferred revenues
of $1,250,000.
|
·
|
Upon
the achievement of commercialization (i.e., regulatory approval by the
MHLW), we will be entitled to an additional nonrefundable payment of
$250,000.
|
·
|
Qualifying
costs incurred (and not previously recognized) to date, plus any allowable
grant fees for which we are entitled to funding from the NIH;
or
|
·
|
The
outputs generated to date versus the total outputs expected to be achieved
under the research arrangement.
|
As of
January 1,
|
Additions/
(Deductions) to
expenses
|
Claims
|
As of
December 31,
|
|||||||||||||
2008:
|
||||||||||||||||
Warranty
obligations
|
$ | 67,000 | $ | (44,000 | ) | $ | — | $ | 23,000 | |||||||
2007:
|
||||||||||||||||
Warranty
obligations
|
$ | 132,000 | $ | (65,000 | ) | $ | — | $ | 67,000 | |||||||
2006:
|
||||||||||||||||
Warranty
obligations
|
$ | 155,000 | $ | (23,000 | ) | $ | — | $ | 132,000 |
Years ended December 31,
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Revenues:
|
||||||||||||
Regenerative
cell technology
|
$ | 6,853,000 | $ | 5,247,000 | $ | 6,324,000 | ||||||
MacroPore
Biosurgery
|
— | 802,000 | 1,603,000 | |||||||||
Total
revenues
|
$ | 6,853,000 | $ | 6,049,000 | $ | 7,927,000 | ||||||
Segment
operating income (losses):
|
||||||||||||
Regenerative
cell technology
|
(16,793,000 | ) | $ | (17,075,000 | ) | $ | (16,211,000 | ) | ||||
MacroPore
Biosurgery
|
(181,000 | ) | 9,000 | (1,528,000 | ) | |||||||
General
and administrative expenses
|
(11,727,000 | ) | (14,184,000 | ) | (12,547,000 | ) | ||||||
Changes
in fair value of option liabilities
|
(1,060,000 | ) | (100,000 | ) | 4,431,000 | |||||||
Total
operating loss
|
$ | (29,761,000 | ) | $ | (31,350,000 | ) | $ | (25,855,000 | ) |
As of December 31,
|
||||||||
2008
|
2007
|
|||||||
Assets:
|
||||||||
Regenerative
cell technology
|
$ | 13,240,000 | $ | 11,591,000 | ||||
MacroPore
Biosurgery
|
— | — | ||||||
Corporate
assets
|
12,369,000 | 9,916,000 | ||||||
Total
assets
|
$ | 25,609,000 | $ | 21,507,000 |
For the Years Ended
December 31,
|
U.S. Revenues
|
Non-U.S. Revenues
|
Total Revenues
|
|||||||||
2008
|
$ | 2,290,000 | $ | 4,563,000 | $ | 6,853,000 | ||||||
2007
|
$ | 6,010,000 | $ | 39,000 | $ | 6,049,000 | ||||||
2006
|
$ | 7,827,000 | $ | 100,000 | $ | 7,927,000 |
As of
December 31,
|
U.S. Domiciled
|
Non-U.S. Domiciled
|
Total
|
|||||||||
2008
|
$ | 3,197,000 | $ | 408,000 | $ | 3,605,000 | ||||||
2007
|
$ | 3,932,000 | $ | 337,000 | $ | 4,269,000 |
3.
|
Transactions
with Olympus Corporation
|
·
|
Olympus
paid $30,000,000 for its 50% interest in the Joint
Venture. Moreover, Olympus simultaneously entered into a
License/Joint Development Agreement with the Joint Venture and us to
develop a second generation commercial system and manufacturing
capabilities.
|
·
|
We
licensed our device technology, including the Celution® System platform
and certain related intellectual property, to the Joint Venture for use in
future generation devices. These devices will process and
purify regenerative cells residing in adipose tissue for various
therapeutic clinical applications. In exchange for this
license, we received a 50% interest in the Joint Venture, as well as an
initial $11,000,000 payment from the Joint Venture; the source of this
payment was the $30,000,000 contributed to the Joint Venture by
Olympus. Moreover, upon receipt of a CE mark for the Celution®
600 in January 2006, we received an additional $11,000,000 development
milestone payment from the Joint
Venture.
|
December
31, 2008
|
December
31, 2007
|
November
4, 2005
|
||||||||||
Expected
volatility of
Cytori
|
68.00 | % | 60.00 | % | 63.20 | % | ||||||
Expected
volatility of the Joint Venture
|
68.00 | % | 60.00 | % | 69.10 | % | ||||||
Bankruptcy
recovery rate for
Cytori
|
21.00 | % | 21.00 | % | 21.00 | % | ||||||
Bankruptcy
threshold for
Cytori
|
$ | 16,740,000 | $ | 9,324,000 | $ | 10,780,000 | ||||||
Probability
of a change of control event for Cytori
|
2.80 | % | 2.17 | % | 3.04 | % | ||||||
Expected
correlation between fair values of Cytori and the Joint Venture in the
future
|
99.00 | % | 99.00 | % | 99.00 | % | ||||||
Risk
free interest
rate
|
2.25 | % | 4.04 | % | 4.66 | % |
December
31, 2008
|
December
31, 2007
|
|||||||
(Unaudited)
|
(Unaudited)
|
|||||||
Balance
Sheets
|
||||||||
Assets:
|
||||||||
Cash
|
$ | 646,000 | $ | 713,000 | ||||
Amounts
due from related party
|
24,000 | — | ||||||
Prepaid
insurance
|
9,000 | 9,000 | ||||||
Computer
equipment and software, net
|
20,000 | 24,000 | ||||||
Total
assets
|
$ | 699,000 | $ | 746,000 | ||||
Liabilities
and Stockholders’ Equity:
|
||||||||
Accrued
expenses
|
$ | 36,000 | $ | 27,000 | ||||
Amounts
due to related
party
|
16,000 | 72,000 | ||||||
Stockholders’
equity
|
647,000 | 647,000 | ||||||
Total
liabilities and stockholders’ equity
|
$ | 699,000 | $ | 746,000 |
Years
ended December 31,
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Statements
of Operation
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|||||||||
Revenues:
|
||||||||||||
Royalty
revenue
|
$ | 157,000 | $ | — | $ | — | ||||||
Operating
expenses:
|
||||||||||||
Research
and development expense
|
— | — | 11,000,000 | |||||||||
General
and administrative expense:
|
||||||||||||
Accounting
and other corporate services
|
75,000 | 40,000 | 172,000 | |||||||||
Quality
system services
|
64,000 | 36,000 | - | |||||||||
Other
|
24,000 | 10,000 | 2,000 | |||||||||
Operating
expenses
|
163,000 | 86,000 | 11,174,000 | |||||||||
Operating
loss
|
(6,000 | ) | (86,000 | ) | (11,174,000 | ) | ||||||
Other
income (expense):
|
||||||||||||
Interest
income
|
5,000 | 7,000 | - | |||||||||
Net
loss
|
$ | ( 1,000 | ) | $ | (79,000 | ) | $ | (11,174,000 | ) | |||
Reconciliation
to equity loss from investment in joint venture
|
||||||||||||
Net
loss
|
$ | ( 1,000 | ) | $ | (79,000 | ) | $ | (11,174,000 | ) | |||
Intercompany
eliminations
|
88,000 | (65,000 | ) | (11,026,000 | ) | |||||||
Net
loss after intercompany eliminations
|
(89,000 | ) | (14,000 | ) | (148,000 | ) | ||||||
Cytori’s
percentage of interest in joint venture
|
50 | % | 50 | % | 50 | % | ||||||
Cytori’s
equity loss from investment in joint
venture
|
$ | (45,000 | ) | $ | (7,000 | ) | $ | (74,000 | ) |
·
|
Level
1: Quoted prices in active markets for identical assets or
liabilities.
|
·
|
Level
2: Quoted prices for similar assets or liabilities in active markets;
quoted prices for identical or similar instruments in markets that are not
active; and model-derived valuations in which all significant inputs are
observable in active markets.
|
·
|
Level
3: Valuations derived from valuation techniques in which one or more
significant inputs are unobservable in active
markets.
|
Balance
as of
|
Basis
of Fair Value Measurements
|
|||||||||||||||
December
31, 2008
|
Level
1
|
Level
2
|
Level
3
|
|||||||||||||
Assets:
|
||||||||||||||||
Cash
equivalents
|
$ | 11,718,000 | $ | 11,718,000 | $ | — | $ | — | ||||||||
Liabilities:
|
||||||||||||||||
Put
option liability
|
$ | (2,060,000 | ) | $ | — | $ | — | $ | (2,060,000 | ) | ||||||
Year
ended
|
Year
ended
|
|||||||
Put
option liability
|
December
31, 2008
|
December
31, 2007
|
||||||
Beginning
balance
|
$ | (1,000,000 | ) | $ | (900,000 | ) | ||
Increase in
fair value recognized in operating expenses
|
(1,060,000 | ) | (100,000 | ) | ||||
Ending
balance
|
$ | (2,060,000 | ) | $ | (1,000,000 | ) | ||
5.
|
Gain
on Sale of Assets
|
Carrying
Value Prior to Disposition
|
||||
Inventory
|
$ | 94,000 | ||
Other
current assets
|
17,000 | |||
Assets
held for sale
|
436,000 | |||
Goodwill
|
465,000 | |||
$ | 1,012,000 |
Years
ended December 31,
|
||||||||
2007
|
2006
|
|||||||
Revenues
|
$ | 792,000 | $ | 1,451,000 | ||||
Cost
of product revenues
|
(422,000 | ) | (1,634,000 | ) | ||||
Research
& development
|
(113,000 | ) | (1,052,000 | ) | ||||
Sales
& marketing
|
(21,000 | ) | (163,000 | ) |
6.
|
Thin
Film Japan Distribution Agreement
|
·
|
Anti-adhesion,
|
·
|
Soft
tissue support, and
|
·
|
Minimization
of the attachment of soft tissues throughout the
body.
|
7.
|
Short-term
Investments
|
8.
|
Composition
of Certain Financial Statement
Captions
|
December
31,
|
December
31,
|
|||||||
2008
|
2007
|
|||||||
Raw
materials
|
$ | 712,000 | $ | — | ||||
Work
in process
|
347,000 | — | ||||||
Finished
goods
|
1,084,000 | — | ||||||
$ | 2,143,000 | $ | — |
December
31,
|
December
31,
|
|||||||
2008
|
2007
|
|||||||
Prepaid
insurance
|
$ | 208,000 | $ | 287,000 | ||||
Prepaid
other
|
390,000 | 411,000 | ||||||
Capitalized
debt issuance costs, current
|
252,000 | — | ||||||
Other
receivables
|
313,000 | 66,000 | ||||||
$ | 1,163,000 | $ | 764,000 |
December
31,
|
December
31,
|
|||||||
2008
|
2007
|
|||||||
Manufacturing
and development equipment
|
$ | 2,996,000 | $ | 2,833,000 | ||||
Office
and computer equipment
|
2,665,000 | 2,430,000 | ||||||
Leasehold
improvements
|
3,125,000 | 3,124,000 | ||||||
8,786,000 | 8,387,000 | |||||||
Less
accumulated depreciation and amortization
|
(6,234,000 | ) | (4,955,000 | ) | ||||
$ | 2,552,000 | $ | 3,432,000 |
December
31,
|
December
31,
|
|||||||
2008
|
2007
|
|||||||
Accrued
legal fees
|
$ | 1,196,000 | $ | 2,749,000 | ||||
Accrued
R&D studies
|
1,110,000 | 1,263,000 | ||||||
Accounts
payable
|
464,000 | 479,000 | ||||||
Accrued
vacation
|
774,000 | 816,000 | ||||||
Accrued
bonus
|
— | 886,000 | ||||||
Accrued
expenses
|
842,000 | 623,000 | ||||||
Deferred
rent
|
305,000 | 265,000 | ||||||
Warranty
reserve
|
23,000 | 67,000 | ||||||
Accrued
accounting fees
|
302,000 | 131,000 | ||||||
Accrued
payroll
|
72,000 | 70,000 | ||||||
$ | 5,088,000 | $ | 7,349,000 |
9.
|
Commitments
and Contingencies
|
Years
Ending December 31,
|
Operating
Leases
|
|||
2009
|
1,754,000 | |||
2010
|
814,000 | |||
2011
|
85,000 | |||
2012
|
60,000 | |||
2013
|
25,000 | |||
2014
|
8,000 | |||
Total
|
$ | 2,746,000 |
10.
|
License
Agreement
|
11.
|
Long-term
Obligations
|
Origination Date
|
Original
Loan Amount
|
Interest
Rate
|
Current
Monthly
Payment*
|
Term
|
Remaining
Principal
(Face
Value)
|
||||||||||||
October
2008
|
$ | 7,500,000 | 10.58 | % | $ | 71,000 |
37
Months
|
$ | 7,500,000 |
Reconciliation
of Face Value to Book Value
|
||||
Total
debt and lease obligation, including final payment fee (Face
Value)
|
$ | 7,914,000 | ||
Less:
Debt Discount
|
(823,000 | ) | ||
Total:
|
7,091,000 | |||
Less:
Current Portion
|
(2,047,000 | ) | ||
Long-Term
Obligation
|
$ | 5,044,000 |
12.
|
Income
Taxes
|
2008
|
2007
|
2006
|
||||||||||
Income
tax expense (benefit) at federal statutory rate
|
(34.00 | )% | (34.00 | )% | (34.00 | )% | ||||||
Stock
based
compensation
|
0.56 | % | 0.92 | % | 0.99 | % | ||||||
Credits
|
(1.67 | )% | (4.87 | )% | (2.72 | )% | ||||||
Change
in federal valuation
allowance
|
38.38 | % | 41.62 | % | 34.52 | % | ||||||
Equity
loss on investment in Joint Venture
|
0.06 | % | 0.01 | % | 0.12 | % | ||||||
Other,
net
|
(3.33 | )% | (3.68 | )% | 1.09 | % | ||||||
0.00 | % | 0.00 | % | 0.00 | % |
2008
|
2007
|
|||||||
Deferred
tax assets:
|
||||||||
Allowances
and reserves
|
$ | 84,000 | $ | 55,000 | ||||
Accrued
expenses
|
452,000 | 582,000 | ||||||
Deferred
revenue and gain on sale of assets
|
4,950,000 | 5,910,000 | ||||||
Stock
based compensation
|
2,965,000 | 2,528,000 | ||||||
Net
operating loss carryforwards
|
48,265,000 | 37,704,000 | ||||||
Income
tax credit carryforwards
|
4,665,000 | 4,140,000 | ||||||
Capitalized
assets and other
|
371,000 | 284,000 | ||||||
Property
and equipment, principally due to differences in
depreciation
|
549,000 | — | ||||||
62,301,000 | 51,203,000 | |||||||
Valuation
allowance
|
(61,965,000 | ) | (50,435,000 | ) | ||||
Total
deferred tax assets, net of allowance
|
336,000 | 768,000 | ||||||
Deferred
tax liabilities:
|
||||||||
Property
and equipment, principally due to differences in
depreciation
|
— | (338,000 | ) | |||||
Intangibles
|
(336,000 | ) | (430,000 | ) | ||||
Other
|
— | — | ||||||
Total
deferred tax liability
|
(336,000 | ) | (768,000 | ) | ||||
Net
deferred tax assets (liability)
|
$ | — | $ | — |
Unrecognized
Tax Benefits – December 31, 2007
|
$ | 716,000 | ||
Gross
increases – tax positions in prior period
|
— | |||
Gross
decreases – tax positions in prior period
|
— | |||
Gross
increase – current-period tax positions
|
236,000 | |||
Settlements
|
— | |||
Lapse
of statute of limitations
|
— | |||
Unrecognized
Tax Benefits – December 31, 2008
|
$ | 952,000 |
13.
|
Employee
Benefit Plan
|
14.
|
Stockholders’
Deficit
|
15.
|
Stockholders
Rights Plan
|
16.
|
Stock-based
Compensation
|
·
|
12/48
of a granted award will vest after one year of service, while an
additional 1/48 of the award will vest at the end of each month thereafter
for 36 months, or
|
·
|
1/48
of the award will vest at the end of each month over a four-year
period.
|
Options
|
Weighted
Average Exercise Price
|
|||||||
Balance
as of January 1, 2008
|
6,007,275 | $ | 4.85 | |||||
Granted
|
534,250 | $ | 5.21 | |||||
Exercised
|
(388,536 | ) | $ | 2.04 | ||||
Expired
|
(146,777 | ) | $ | 6.50 | ||||
Cancelled/forfeited
|
(77,505 | ) | $ | 5.68 | ||||
Balance
as of December 31, 2008
|
5,928,707 | $ | 5.02 |
Options
|
Weighted
Average Exercise Price
|
Weighted
Average Remaining Contractual Term (years)
|
Aggregate
Intrinsic Value
|
|||||||||||||
Balance
as of December 31, 2008
|
5,928,707 | $ | 5.02 | 5.34 | $ | 936,815 | ||||||||||
Vested
and expected to vest at December 31, 2008
|
5,825,490 | $ | 5.00 | 5.29 | $ | 933,678 | ||||||||||
Vested
and exercisable at December 31, 2008
|
4,775,056 | $ | 4.85 | 4.62 | $ | 901,759 |
Options
Outstanding
|
Options
Exercisable
|
|||||||||||||||||||||
Range of Exercise Price
|
Number
of Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual Life
in Years
|
Number
of Shares
|
Weighted
Average
Exercise
Price
|
|||||||||||||||||
Less
than $2.00
|
32,218 | $ | 0.72 | 0.5 | 32,218 | $ | 0.72 | |||||||||||||||
$ | 2.00 – 3.99 | 1,538,168 | $ | 3.06 | 3.7 | 1,488,784 | $ | 3.07 | ||||||||||||||
$ | 4.00 – 5.99 | 2,759,822 | $ | 4.76 | 6.4 | 1,989,179 | $ | 4.56 | ||||||||||||||
$ | 6.00 – 7.99 | 1,265,332 | $ | 6.84 | 5.1 | 1,013,064 | $ | 6.89 | ||||||||||||||
$ | 8.00 – 9.99 | 256,167 | $ | 8.67 | 6.9 | 174,811 | $ | 8.68 | ||||||||||||||
More
than $10.00
|
77,000 | $ | 13.18 | 1.2 | 77,000 | $ | 13.18 | |||||||||||||||
5,928,707 | 4,775,056 |
Years
ended December 31,
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Expected
term
|
5
years
|
6
years
|
6
years
|
|||||||||
Risk-free
interest rate
|
2.83 | % | 4.59 | % | 4.50 | % | ||||||
Volatility
|
59.62 | % | 74.61 | % | 78.61 | % | ||||||
Dividends
|
— | — | — | |||||||||
Resulting
weighted average grant date fair value
|
$ | 2.77 | $ | 3.74 | $ | 5.26 |
Years
ended December 31,
|
||||||||||||
2008
|
2007
|
2006
|
||||||||||
Total
compensation cost for share-based payment arrangements recognized in the
statement of operations (net of tax of $0)
|
$ | 2,257,000 | $ | 2,310,000 | $ | 3,220,000 |
17.
|
Related
Party Transactions
|
18.
|
Quarterly
Information (unaudited)
|
For the three months ended
|
||||||||||||||||
March 31,
2008
|
June 30,
2008
|
September 30,
2008
|
December 31,
2008
|
|||||||||||||
Product
revenues
|
$ | 153,000 | $ | 1,404,000 | $ | 2,319,000 | $ | 652,000 | ||||||||
Gross
profit
|
93,000 | 729,000 | 1,671,000 | 181,000 | ||||||||||||
Development
revenues
|
811,000 | 12,000 | 1,000 | 1,501,000 | ||||||||||||
Operating
expenses
|
9,232,000 | 9,113,000 | 8,481,000 | 7,934,000 | ||||||||||||
Other
income
|
55,000 | (41,000 | ) | (8,000 | ) | (281,000 | ) | |||||||||
Net
loss
|
$ | (8,273,000 | ) | $ | (8,413,000 | ) | $ | (6,817,000 | ) | $ | (6,533,000 | ) | ||||
Basic
and diluted net loss per share
|
$ | (0.34 | ) | $ | (0.33 | ) | $ | (0.24 | ) | $ | (0.22 | ) |
For the three months ended
|
||||||||||||||||
March 31,
2007
|
June 30,
2007
|
September 30,
2007
|
December 31,
2007
|
|||||||||||||
Product
revenues
|
$ | 280,000 | $ | 512,000 | $ | — | $ | — | ||||||||
Gross
profit
|
55,000 | 315,000 | — | — | ||||||||||||
Development
revenues
|
45,000 | 1,814,000 | 3,373,000 | 25,000 | ||||||||||||
Operating
expenses
|
8,908,000 | 8,245,000 | 8,983,000 | 10,841,000 | ||||||||||||
Other
income
|
139,000 | 2,120,000 | 282,000 | 137,000 | ||||||||||||
Net
loss
|
$ | (8,669,000 | ) | $ | (3,996,000 | ) | $ | (5,328,000 | ) | $ | (10,679,000 | ) | ||||
Basic
and diluted net loss per share
|
$ | (0.43 | ) | $ | (0.17 | ) | $ | (0.22 | ) | $ | (0.44 | ) |
(a)
(1)
|
Financial
Statements
|
|
(a)
(2)
|
Financial
Statement Schedules
|
Balance at
beginning of
year
|
Additions/(Reductions)
((charges)/ credits to
expense)
|
Charged to
Other
Accounts
|
Deductions
|
Balance at
end of year
|
||||||||||||||||
Allowance for doubtful
accounts
|
||||||||||||||||||||
Year
ended December 31, 2008
|
$ | 1 | $ | 121 | $ | — | $ | — | $ | 122 | ||||||||||
Year
ended December 31, 2007
|
$ | 2 | $ | 1 | $ | — | $ | (2 | ) | $ | 1 | |||||||||
Year
ended December 31, 2006
|
$ | 9 | $ | — | $ | — | $ | (7 | ) | $ | 2 |
(a)
(3)
|
Exhibits
|
Exhibit
Number
|
Description
|
|
2.5
|
Asset
Purchase Agreement dated May 30, 2007, by and
between Cytori Therapeutics, Inc. and MacroPore Acquisition Sub, Inc
(filed as Exhibit 2.5 to our Form 10-Q Quarterly Report as
filed on August 14, 2007 and incorporated by reference
herein)
|
|
3.1
|
Amended
and Restated Certificate of Incorporation (filed as Exhibit 3.1
to our Form 10-Q Quarterly Report as filed on August 13, 2002 and
incorporated by reference herein)
|
|
3.2
|
Amended
and Restated Bylaws of Cytori Therapeutics, Inc. (filed as
Exhibit 3.2 to our Form 10-Q Quarterly Report, as filed on
August 14, 2003 and incorporated by reference herein)
|
|
3.3
|
Certificate
of Ownership and Merger (effecting name change to Cytori Therapeutics,
Inc.) (filed as Exhibit 3.1.1 to our Form 10-Q, as filed on November 14,
2005 and incorporated by reference herein)
|
|
4.1
|
Rights
Agreement, dated as of May 19, 2003, between Cytori Therapeutics, Inc. and
Computershare Trust Company, Inc. as Rights Agent, which includes: as
Exhibit A thereto, the Form of Certificate of Designation, Preferences and
Rights of Series RP Preferred Stock of Cytori Therapeutics, Inc.; as
Exhibit B thereto, the Form of Right Certificate; and, as Exhibit C
thereto, the Summary of Rights to Purchase Series RP Preferred Stock
(filed as Exhibit 4.1 to our Form 8-A which was filed on May 30, 2003 and
incorporated by reference herein)
|
|
4.1.1
|
Amendment
No. 1 to Rights Agreement dated as of May 12, 2005, between Cytori
Therapeutics, Inc. and Computershare Trust Company, Inc. as Rights Agent
(filed as Exhibit 4.1.1 to our Form 8-K, which was filed on May 18, 2005
and incorporated by reference herein).
|
|
4.1.2
|
Amendment
No. 2 to Rights Agreement, dated as of August 28, 2007, between us and
Computershare Trust Company, N.A. (as successor to Computershare Trust
Company, Inc.), as Rights Agent (filed as Exhibit 4.1.1 to our Form 8-K,
which was filed on September 4, 2007 and incorporated by reference
herein).
|
|
10.1#
|
Amended
and Restated 1997 Stock Option and Stock Purchase Plan (filed as
Exhibit 10.1 to our Form 10 registration statement, as amended,
as filed on March 30, 2001 and incorporated by reference
herein)
|
|
10.1.1#
|
Board
of Directors resolution adopted November 9, 2006 regarding determination
of fair market value for stock option grant purposes (incorporated by
reference to Exhibit 10.10.1 filed as exhibit 10.10.1 to our Form 10-K
Annual Report, as filed on March 30, 2007 and incorporated by
reference herein)
|
|
10.2+
|
Development
and Supply Agreement, made and entered into as of January 5, 2000, by
and between the Company and Medtronic (filed as Exhibit 10.4 to our
Form 10 registration statement, as amended, as filed on June 1,
2001 and incorporated by reference herein)
|
|
10.3+
|
Amendment
No. 1 to Development and Supply Agreement, effective as of
December 22, 2000, by and between the Company and Medtronic (filed as
Exhibit 10.5 to our Form 10 registration statement, as amended,
as filed on June 1, 2001 and incorporated by reference
herein)
|
|
10.4+
|
License
Agreement, effective as of October 8, 2002, by and between the Company and
Medtronic PS Medical, Inc. (filed as Exhibit 2.2 to our Current
Report on Form 8-K which was filed on October 23, 2002 and
incorporated by reference herein)
|
|
10.5+
|
Amendment
No. 2 to Development and Supply Agreement, effective as of September
30, 2002, by and between the Company and Medtronic, Inc. (filed as
Exhibit 2.4 to our Current Report on Form 8-K which was filed on
October 23, 2002 and incorporated by reference herein)
|
|
10.7
|
Amended
Master Security Agreement between the Company and General Electric
Corporation, September, 2003 (filed as Exhibit 10.1 to our
Form 10-Q Quarterly Report, as filed on November 12, 2003 and
incorporated by reference herein)
|
|
10.8#
|
Asset
Purchase Agreement dated May 7, 2004 between Cytori Therapeutics, Inc. and
MAST Biosurgery AG (filed as Exhibit 2.1 to our Form 8-K Current Report,
as filed on May 28, 2004 and incorporated by reference
herein.)
|
|
10.8.1
|
Settlement
Agreement dated August 9, 2005, between MAST Biosurgery AG, MAST
Biosurgery, Inc. and the Company (filed as Exhibit 10.26 to our Form 10-Q,
which was filed on November 14, 2005 and incorporated by reference
herein)
|
|
10.9#
|
Offer
Letter for the Position of Chief Financial Officer dated June 2, 2004
between the Company and Mark Saad (filed as Exhibit 10.18 to our
Form 10-Q Quarterly Report, as filed on August 16, 2004 and
incorporated by reference herein)
|
|
10.10#
|
2004
Equity Incentive Plan of Cytori Therapeutics, Inc. (filed as
Exhibit 10.1 to our Form 8-K Current Report, as filed on August
27, 2004 and incorporated by reference herein)
|
|
10.10.1#
|
Board
of Directors resolution adopted November 9, 2006 regarding determination
of fair market value for stock option grant purposes (filed as
Exhibit 10.10.1 to our Form 10-K Annual Report, as filed on
March 30, 2007 and incorporated by reference herein)
|
|
10.11
|
Exclusive
Distribution Agreement, effective July 16, 2004 by and between the Company
and Senko Medical Trading Co. (filed as Exhibit 10.25 to our
Form 10-Q Quarterly Report, as filed on November 15, 2004 and
incorporated by reference herein)
|
|
10.12#
|
Notice
and Agreement for Stock Options Grant Pursuant to Cytori Therapeutics,
Inc. 1997 Stock Option and Stock Purchase Plan; (Nonstatutory) (filed as
Exhibit 10.19 to our Form 10-Q Quarterly Report, as filed on
November 15, 2004 and incorporated by reference herein)
|
|
|
||
10.13#
|
Notice
and Agreement for Stock Options Grant Pursuant to Cytori Therapeutics,
Inc. 1997 Stock Option and Stock Purchase Plan; (Nonstatutory) with Cliff
(filed as Exhibit 10.20 to our Form 10-Q Quarterly Report, as
filed on November 15, 2004 and incorporated by reference
herein)
|
|
10.14#
|
Notice
and Agreement for Stock Options Grant Pursuant to Cytori Therapeutics,
Inc. 1997 Stock Option and Stock Purchase Plan; (Incentive) (filed as
Exhibit 10.21 to our Form 10-Q Quarterly Report, as filed on
November 15, 2004 and incorporated by reference herein)
|
|
10.15#
|
Notice
and Agreement for Stock Options Grant Pursuant to Cytori Therapeutics,
Inc. 1997 Stock Option and Stock Purchase Plan; (Incentive) with Cliff
(filed as Exhibit 10.22 to our Form 10-Q Quarterly Report, as
filed on November 15, 2004 and incorporated by reference
herein)
|
|
10.16#
|
Form
of Options Exercise and Stock Purchase Agreement Relating to the 2004
Equity Incentive Plan (filed as Exhibit 10.23 to our Form 10-Q
Quarterly Report, as filed on November 15, 2004 and incorporated by
reference herein)
|
|
10.17#
|
Form
of Notice of Stock Options Grant Relating to the 2004 Equity Incentive
Plan (filed as Exhibit 10.24 to our Form 10-Q Quarterly Report,
as filed on November 15, 2004 and incorporated by reference
herein)
|
|
10.18#
|
Separation
Agreement and General Release dated July 15, 2005, between John K. Fraser
and the Company (filed as Exhibit 10.25 to our Form 10-Q Quarterly Report
as filed on November 14, 2005 and incorporated by reference
herein)
|
|
10.19#
|
Consulting
Agreement dated July 15, 2005, between John K. Fraser and the Company
(filed as Exhibit 10.28 to our Form 10-Q Quarterly Report as filed on
November 14, 2005 and incorporated by reference herein)
|
|
10.20
|
Agreement
Between Owner and Contractor dated October 10, 2005, between Rudolph and
Sletten, Inc. and the Company (filed as Exhibit 10.20 to our Form 10-K
Annual Report as filed on March 30, 2006 and incorporated by reference
herein)
|
|
10.21#
|
Severance
Agreement and General Release dated August 10, 2005, between Sharon V.
Schulzki and the Company (filed as Exhibit 10.27 to our Form 10-Q
Quarterly report as filed on November 14, 2005 and incorporated by
reference herein)
|
|
10.22
|
Common
Stock Purchase Agreement dated April 28, 2005, between Olympus Corporation
and the Company (filed as Exhibit 10.21 to our Form 10-Q Quarterly Report
as filed on August 15, 2005 and incorporated by reference
herein)
|
|
10.23
|
Sublease
Agreement dated May 24, 2005, between Biogen Idec, Inc. and the Company
(filed as Exhibit 10.21 to our Form 10-Q Quarterly Report as filed on
August 15, 2005 and incorporated by reference herein)
|
|
10.24#
|
Employment
Offer Letter to Doug Arm, Vice President of Development—Biologics, dated
February 1, 2005 (filed as Exhibit 10.21 to our Form 10-Q Quarterly Report
as filed on August 15, 2005 and incorporated by reference
herein)
|
|
10.25#
|
Employment
Offer Letter to Alex Milstein, Vice-President of Clinical Research, dated
May 1, 2005 (filed as Exhibit 10.21 to our Form 10-Q Quarterly Report as
filed on August 15, 2005 and incorporated by reference
herein)
|
|
10.26#
|
Employment
Offer Letter to John Ransom, Vice-President of Research, dated November
15, 2005 (filed as Exhibit 10.26 to our Form 10-K Annual Report as filed
on March 30, 2006 and incorporated by reference herein)
|
|
10.27+
|
Joint
Venture Agreement dated November 4, 2005, between Olympus Corporation and
the Company (filed as Exhibit 10.27 to our Form 10-K Annual Report as
filed on March 30, 2006 and incorporated by reference
herein)
|
|
10.28+
|
License/
Commercial Agreement dated November 4, 2005, between Olympus-Cytori, Inc.
and the Company (filed as Exhibit 10.28 to our Form 10-K Annual Report as
filed on March 30, 2006 and incorporated by reference
herein)
|
|
10.28.1
|
Amendment
One to License/ Commercial Agreement dated November 14, 2007, between
Olympus-Cytori, Inc. and the Company (filed as Exhibit 10.28.1 to our Form
10-K Annual Report as filed on March 14, 2008 and incorporated by
reference herein).
|
|
10.29+
|
License/
Joint Development Agreement dated November 4, 2005, between Olympus
Corporation, Olympus-Cytori, Inc. and the Company (filed as Exhibit 10.29
to our Form 10-K Annual Report as filed on March 30, 2006 and incorporated
by reference herein)
|
|
10.29.1
|
Amendment
No. 1 to License/ Joint Development Agreement dated May 20, 2008, between
Olympus Corporation, Olympus-Cytori, Inc. and the Company (filed as
Exhibit 10.29.1 to our Form 10-Q Quarterly Report as filed on August 11,
2008 and incorporated by reference herein).
|
|
10.30+
|
Shareholders
Agreement dated November 4, 2005, between Olympus Corporation and the
Company (filed as Exhibit 10.30 to our Form 10-K Annual Report as filed on
March 30, 2006 and incorporated by reference herein)
|
|
10.31+
|
Exclusive
Negotiation Agreement with Olympus Corporation, dated February 22, 2006
(filed as Exhibit 10.31 to our Form 10-Q Quarterly Report as filed on May
15, 2006 and incorporated by reference herein)
|
|
10.32
|
Common
Stock Purchase Agreement, dated August 9, 2006, by and between Cytori
Therapeutics, Inc. and Olympus Corporation (filed as Exhibit 10.32 to our
Form 8-K Current Report as filed on August 15, 2006 and incorporated by
reference herein)
|
|
10.33
|
Form
of Common Stock Subscription Agreement, dated August 9, 2006 (Agreements
on this form were signed by Cytori and each of respective investors in the
Institutional Offering) (filed as Exhibit 10.33 to our Form 8-K Current
Report as filed on August 15, 2006 and incorporated by reference
herein)
|
|
10.34
|
Placement
Agency Agreement, dated August 9, 2006, between Cytori Therapeutics, Inc.
and Piper Jaffray & Co. (filed as Exhibit 10.34 to our Form 8-K
Current Report as filed on August 15, 2006 and incorporated by reference
herein)
|
|
10.35#
|
Stock
Option Extension Agreement between Bruce A. Reuter and Cytori
Therapeutics, Inc. effective July 25, 2006 (filed as Exhibit 10.35 to our
Form 10-Q Quarterly Report as filed on November 145, 2006 and incorporated
by reference herein)
|
|
10.36#
|
Stock
Option Extension Agreement between Elizabeth A. Scarbrough and Cytori
Therapeutics, Inc. effective July 25, 2006 (filed as Exhibit 10.36 to our
Form 10-Q Quarterly Report as filed on November 14, 2006 and incorporated
by reference herein)
|
|
10.37#
|
Employment
Agreement between Bruce A. Reuter and Cytori Therapeutics, Inc. effective
July 25, 2006 (filed as Exhibit 10.37 to our Form 10-Q Quarterly Report as
filed on November 14, 2006 and incorporated by reference
herein)
|
|
10.38#
|
Employment
Agreement between Elizabeth A. Scarbrough and Cytori Therapeutics, Inc.
effective July 25, 2006 (filed as Exhibit 10.38 to our Form 10-Q Quarterly
Report as filed on November 14, 2006 and incorporated by reference
herein)
|
|
10.39+
|
Exclusive
License Agreement between us and the Regents of the University of
California dated October 16, 2001 (filed as Exhibit 10.10 to our Form 10-K
Annual Report as filed on March 31, 2003 and incorporated by reference
herein)
|
|
10.39.1
+
|
Amended
and Restated Exclusive License Agreement, effective September 26, 2006, by
and between The Regents of the University of California and Cytori
Therapeutics, Inc. (filed as Exhibit 10.39 to our Form 10-Q Quarterly
Report as filed on November 14, 2006 and incorporated by reference
herein)
|
|
10.40#
|
Stock
Option Extension Agreement between Charles Galetto and Cytori
Therapeutics, Inc. signed on May 24, 2006 and effective as of June 1, 2006
(filed as Exhibit 10.20 to our Form 10-Q Quarterly Report as filed on
August 14, 2006 and incorporated by reference herein)
|
|
10.41#
|
Part-time
Employment Agreement between Charles Galetto and Cytori Therapeutics, Inc.
signed on May 24, 2006 and effective as of June 1, 2006 (filed as Exhibit
10.21 to our Form 10-Q Quarterly Report as filed on August 14, 2006 and
incorporated by reference herein)
|
|
10.42
|
Placement
Agency Agreement, dated February 23, 2007, between Cytori Therapeutics,
Inc. and Piper Jaffray & Co. (filed as Exhibit 10.1 to our
Form 8-K Current Report as filed on February 26, 2007 and
incorporated by reference herein).
|
|
10.43
|
Financial
services advisory engagement letter agreement, dated February 16, 2007,
between Cytori Therapeutics, Inc. and WBB Securities, LLC (filed as
Exhibit 10.2 to our Form 8-K Current Report as filed on February 26, 2007
and incorporated by reference herein)
|
|
10.44
|
Form
of Subscription Agreement, dated February 23, 2007 (filed as Exhibit 10.3
to our Form 8-K Current Report as filed on February 26, 2007 and
incorporated by reference herein)
|
|
10.45
|
Form
of Warrant to be dated February 28, 2007 (filed as Exhibit 10.4 to our
Form 8-K Current Report as filed on February 26, 2007 and incorporated by
reference herein)
|
|
10.46
|
Common
Stock Purchase Agreement, dated March 28, 2007, by and between Cytori
Therapeutics, Inc. and Green Hospital Supply, Inc. (filed as Exhibit 10.46
to our Form 10-Q Quarterly Report as filed on May 11, 2007 and
incorporated by reference herein).
|
|
10.47
|
Consulting
Agreement, dated May 3, 2007, by and between Cytori Therapeutics, Inc. and
Marshall G. Cox. (filed as Exhibit 10.47 to our Form 10-Q
Quarterly Report as filed on August 14, 2007 and incorporated by reference
herein).
|
|
10.48+
|
Master
Cell Banking and Cryopreservation Agreement, effective August 13, 2007, by
and between Green Hospital Supply, Inc.
and Cytori
Therapeutics, Inc. (filed as Exhibit 10.48 to our Form 10-Q Quarterly
Report as filed on November 13, 2007 and incorporated by reference
herein).
|
|
10.48.1
|
Amendment
No. 1 to Master Cell Banking and Cryopreservation Agreement, effective
June 4, 2008, by and between Green Hospital Supply, Inc. and the Company
(filed as Exhibit 10.48.1 to our Form 8-K Current Report as filed on June
10, 2008 and incorporated by reference herein).
|
|
10.49+
|
License
& Royalty Agreement, effective August 23, 2007, by and between
Olympus-Cytori, Inc.
and Cytori
Therapeutics, Inc. (filed as Exhibit 10.49 to our Form 10-Q
Quarterly Report as filed on November 13, 2007 and incorporated by
reference herein).
|
|
10.50
|
General
Release Agreement, dated August 13, 2007, between John Ransom and Cytori
Therapeutics, Inc. (filed as Exhibit 10.49 to our Form 10-Q Quarterly
Report as filed on November 13, 2007 and incorporated by reference
herein).
|
|
10.51
|
Common
Stock Purchase Agreement, dated February 8, 2008, by and between Green
Hospital Supply, Inc.
and Cytori
Therapeutics, Inc. (filed as Exhibit 10.51 to our Form 8-K Current Report
as filed on February 19, 2008 and incorporated by reference
herein).
|
|
10.51.1
|
Amendment
No. 1 to Common Stock Purchase Agreement, dated February 29, 2008, by and
between Green Hospital Supply, Inc. and Cytori Therapeutics, Inc. (filed
as Exhibit 10.51.1 to our Form 8-K Current Report as filed on February 29,
2008 and incorporated by reference herein).
|
|
10.52#
|
Agreement
for Acceleration and/or Severance, dated January 31, 2008, by and between
Christopher J. Calhoun
and Cytori
Therapeutics, Inc. (filed as Exhibit 10.52 to our Form 10-K Annual Report
as filed on March 14, 2008 and incorporated by reference
herein).
|
|
10.53#
|
Agreement
for Acceleration and/or Severance, dated January 31, 2008, by and between
Marc H. Hedrick
and Cytori
Therapeutics, Inc. (filed as Exhibit 10.53 to our Form 10-K Annual Report
as filed on March 14, 2008 and incorporated by reference
herein).
|
|
10.54#
|
Agreement
for Acceleration and/or Severance, dated January 31, 2008, by and between
Mark E. Saad
and Cytori
Therapeutics, Inc. (filed as Exhibit 10.54 to our Form 10-K Annual Report
as filed on March 14, 2008 and incorporated by reference
herein).
|
|
10.55
|
Common
Stock Purchase Agreement, dated August 7, 2008, by and between the Company
and Olympus Corporation (filed as Exhibit 10.32 to our current report on
Form 8-K filed on August 8, 2008 and incorporated by reference
herein).
|
|
10.55.1
|
Amendment
No. 1 to Common Stock Purchase Agreement, dated August 8, 2008, by and
between the Company and Olympus Corporation (filed as Exhibit 10.32.1 to
our current report on Form 8-K filed on August 14, 2008 and incorporated
by reference herein).
|
|
10.56
|
Securities
Purchase Agreement, dated August 7, 2008, by and among the Company and the
Purchasers identified on the signature pages thereto (filed as Exhibit
10.33 to our current report on Form 8-K filed on August 8, 2008 and
incorporated by reference herein).
|
|
10.57
|
Form
of Warrant to Purchase Common Stock issued on August 11, 2008 pursuant to
the Securities Purchase Agreement, dated August 7, 2008, by and among the
Company and the Purchasers identified on the signature pages thereto
(filed as Exhibit 10.34 to our current report on Form 8-K filed on August
8, 2008 and incorporated by reference herein).
|
|
10.58
|
Registration
Rights Agreement, dated August 7, 2008, by and among the Company and the
Purchasers identified on the signature pages thereto (filed as Exhibit
10.35 to our current report on Form 8-K filed on August 8, 2008 and
incorporated by reference herein).
|
|
10.59
|
Loan
and Security Agreement, dated October 14, 2008, by and among the Company,
General Electric Capital Corporation, and the other lenders signatory
thereto (filed herewith).
|
|
10.60
|
Promissory
Note issued by the Company in favor of General Electric Capital
Corporation or any subsequent holder thereof, pursuant to the Loan and
Security Agreement dated October 14, 2008 (filed
herewith).
|
|
10.61
|
Warrant
to Purchase Common Stock issued by the Company on October 14, 2008 in
favor of GE Capital Equity Investments, Inc., pursuant to the Loan and
Security Agreement dated October 14, 2008 (filed
herewith).
|
|
10.62
|
Warrant
to Purchase Common Stock issued by the Company on October 14, 2008 in
favor of Silicon Valley Bank, pursuant to the Loan and Security Agreement
dated October 14, 2008 (filed herewith).
|
|
14.1
|
Code
of Ethics (filed as Exhibit 14.1 to our Annual Report on
Form 10-K which was filed on March 30, 2004 and incorporated by
reference herein)
|
|
23.1
|
Consent
of KPMG LLP, Independent Registered Public Accounting Firm (filed
herewith).
|
|
31.1
|
Certification
of Principal Executive Officer Pursuant to Securities Exchange Act Rule
13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002 (filed herewith).
|
|
31.2
|
Certification
of Principal Financial Officer Pursuant to Securities Exchange Act Rule
13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002 (filed herewith).
|
|
32.1
|
Certifications
Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule
13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act
of 2002 (filed herewith).
|
CYTORI
THERAPEUTICS, INC.
|
||
By:
|
/s/
Christopher J. Calhoun
|
|
Christopher
J. Calhoun
|
||
Chief
Executive Officer
|
||
March
6, 2009
|
SIGNATURE
|
TITLE
|
DATE
|
||
/s/
Ronald D. Henriksen
|
Chairman
of the Board of Directors
|
March
6, 2009
|
||
Ronald
D. Henriksen
|
||||
/s/
Christopher J. Calhoun
|
Chief
Executive Officer, Vice-Chairman, Director (Principal Executive
Officer)
|
March
6, 2009
|
||
Christopher
J. Calhoun
|
||||
/s/
Marc H. Hedrick, MD
|
President,
Director
|
March
6, 2009
|
||
Marc
H. Hedrick, MD
|
||||
/s/
Mark E. Saad
|
Chief
Financial Officer (Principal Financial Officer)
|
March
6, 2009
|
||
Mark
E. Saad
|
||||
/s/
John W. Townsend
|
Chief
Accounting Officer
|
March
6, 2009
|
||
John
W. Townsend
|
||||
/s/
David M. Rickey
|
Director
|
March
6, 2009
|
||
David
M. Rickey
|
||||
/s/
Rick Hawkins
|
Director
|
March
6, 2009
|
||
Rick
Hawkins
|
||||
/s/
E. Carmack Holmes, MD
|
Director
|
March
6, 2009
|
||
E.
Carmack Holmes, MD
|
||||
/s/
Paul W. Hawran
|
Director
|
March
6, 2009
|
||
Paul
W. Hawran
|
1.
|
DEFINITIONS.
|
2.
|
LOANS
AND TERMS OF PAYMENT.
|
3.
|
CREATION
OF SECURITY INTEREST.
|
4.
|
CONDITIONS
OF CREDIT EXTENSIONS
|
5.
|
REPRESENTATIONS
AND WARRANTIES OF LOAN PARTIES.
|
6.
|
AFFIRMATIVE
COVENANTS.
|
7.
|
NEGATIVE
COVENANTS
|
8.
|
DEFAULT
AND REMEDIES.
|
9.
|
THE
AGENT.
|
10.
|
MISCELLANEOUS.
|
CYTORI
THERAPEUTICS, INC.
By:
/s/
Mark E. Saad
Name: Mark E.
Saad
Title: Chief
Financial Officer
Federal
Tax ID #: 33-0827593
Address:
3020
Callan Road
San
Diego, California 92121
|
Warrant No. CSW-08-022 | October 14, 2008 |
If
to Company:
|
Cytori
Therapeutics Inc.
|
|
3020
Callan Road
|
|
San
Diego, California 92121
|
Phone: (858) 458-0900 | |
Facsimile: (858) 450-4335 | |
Attn: Chief Financial Officer |
|
With
a copy to:
|
Cytori
Therapeutics Inc.
|
|
3020
Callan Road
|
|
San
Diego, California 92121
|
Phone: (858) 458-0900 | |
Facsimile: (858) 450-4335 | |
Attn: In-House Counsel |
|
If
to Holder:
|
GE
Capital Equity Investments, Inc.
|
201 Merritt 7, 1 st Floor | ||
P.O. Box 5201 | ||
Norwalk, Connecticut 06851 | ||
Facsimile: (203) 205-2192 | ||
Attn: General Counsel | ||
|
With
copies to:
|
General
Electric Capital Corporation
|
|
c/o
GE Healthcare Financial Services,
Inc.
|
|
83
Wooster Heights Road, Fifth Floor
|
Danbury, Connecticut 06810 | |
Facsimile: (203) 205-2192 | |
Attn: Senior Managing Director and | |
Senior Vice President of Risk |
1.
|
The
undersigned Warrantholder (“Holder”) elects to acquire shares of the
Common Stock (the “Common Stock”) of Cytori Therapeutics Inc. (the
“Company”), pursuant to the terms of the Stock Purchase Warrant dated
October 14, 2008 (the “Warrant”).
|
2.
|
Holder
exercises its rights under the Warrant as set forth below (check
one):
|
|
( )
|
Holder
elects to purchase _____________ shares of Common Stock as provided in
Section 3(a) and tenders herewith a check in the amount of
$___________ as payment of the purchase
price.
|
|
( )
|
Holder
elects to convert the purchase rights into shares of Common Stock as
provided in Section 3(b) of the
Warrant.
|
3.
|
Holder
surrenders the Warrant with this Notice of
Exercise.
|
Warrant No. CSW-08-023 | October 14, 2008 |
If
to Company:
|
Cytori
Therapeutics Inc.
|
|
3020
Callan Road
|
|
San
Diego, California 92121
|
Phone: (858) 458-0900 | |
Facsimile: (858) 450-4335 | |
Attn: Chief Financial Officer |
|
With
a copy to:
|
Cytori
Therapeutics, Inc.
|
|
3020
Callan Road
|
|
San
Diego, California 92121
|
Phone: (858) 458-0900 | |
Facsimile: (858) 450-4335 | |
Attn: In-House Counsel |
|
If
to Holder:
|
Silicon
Valley Bank
|
3003 Tasman Drive (HA-200) | ||
Santa Clara, CA 9505 | ||
Facsimile: 408-496-2405 | ||
Phone: 408-654-7400 | ||
Attn: Treasury Department | ||
1.
|
The
undersigned Warrantholder (“Holder”) elects to acquire shares of the
Common Stock (the “Common Stock”) of Cytori Therapeutics Inc. (the
“Company”), pursuant to the terms of the Stock Purchase Warrant dated
October 14, 2008 (the “Warrant”).
|
2.
|
Holder
exercises its rights under the Warrant as set forth below (check
one):
|
|
( )
|
Holder
elects to purchase _____________ shares of Common Stock as provided in
Section 3(a) and tenders herewith a check in the amount of
$___________ as payment of the purchase
price.
|
|
( )
|
Holder
elects to convert the purchase rights into shares of Common Stock as
provided in Section 3(b) of the
Warrant.
|
3.
|
Holder
surrenders the Warrant with this Notice of
Exercise.
|
|
EXHIBIT
23.1
|
/s/
KPMG LLP
|
|
San
Diego, California
|
|
March
6, 2009
|
1.
|
I
have reviewed this annual report on Form 10-K of Cytori Therapeutics,
Inc.;
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;
|
3.
|
Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
report;
|
4.
|
The
registrant’s other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and
have:
|
5.
|
The
registrant’s other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent
functions):
|
Date:
March 6, 2009
|
|
/s/
Christopher J. Calhoun
|
|
Christopher
J. Calhoun,
|
|
Chief
Executive Officer
|
1.
|
I
have reviewed this annual report on Form 10-K of Cytori Therapeutics,
Inc.;
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;
|
3.
|
Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
report;
|
4.
|
The
registrant’s other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and
have:
|
5.
|
The
registrant’s other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent
functions):
|
Date:
March 6, 2009
|
|
/s/
Mark E. Saad
|
|
Mark
E. Saad,
|
|
Chief
Financial Officer
|
1.
|
The
Form 10-K report of Cytori Therapeutics, Inc. that this certification
accompanies fully complies with the requirements of section 13(a) of
the Securities Exchange Act of
1934.
|
2.
|
The
information contained in the Form 10-K report of Cytori Therapeutics, Inc.
that this certification accompanies fairly presents, in all material
respects, the financial condition and results of operations of Cytori
Therapeutics, Inc.
|
By:
|
/s/
Christopher J. Calhoun
|
|
Dated:
March 6, 2009
|
Christopher
J. Calhoun
|
|
Chief
Executive Officer
|
||
By:
|
/s/
Mark E. Saad
|
|
Dated:
March 6, 2009
|
Mark
E. Saad
|
|
Chief
Financial Officer
|